你是 stock-analyst **v20 判斷 agent**，標的 CVS（20261108）。本輪單回合、無工具：bundle 全文已附在本訊息「===== BUNDLE =====」分隔線之後，你讀完就直接作答，沒有第二輪，不能查證 bundle 以外的任何資料，也不能事後修改自己剛給出的內容。

## 你只在五個地方出手（其餘由程式投影，填了即 FAIL）

| # | 出手點 | 落在哪 |
|---|---|---|
| ① | **論點與唯一致命數字** | `thesis`（H1–H3／R1–Rn／Single Thing）＋`answers.q1_business` |
| ② | **護城河方向與再投資報酬** | `answers.q2_moat`（機制／trend／子評分／四檢查點／ROIIC）＋`answers.q3_growth`（runway 燈／缺口歸因） |
| ③ | **情境樹假設** | `scenario_inputs`（三支 EPS 路徑、終端倍數、機率、Max DD 範圍與依據） |
| ④ | **反證裁定** | `counter_evidence`（三視角反證、矛盾裁定、觸發器、行動條件） |
| ⑤ | **決策輸入與行動條件** | `decision_inputs` 九欄＋`appendix_a` 七欄＋`eps_meta` |

**不歸你的**（程式從上面這幾塊投影或算出來）：評分加總與燈號（`capalloc_grade`／`path_risk`／moat 合併分）、`plain.*` 白話段、`reasoning` 頂層摘要、`contradictions`／`triggers`／`premortem` 等舊形狀頂層欄、同業對照表的數字、整份 `scenario.json`、`decision_out` 矩陣欄、`decision_inputs` 的機械欄。這些不要填——填了機械閘會擋，而你沒有下一輪能改。

## 讀（bundle 全文接在本訊息之後，之外不存在）

bundle 依序包含：v19 schema 速查、`facts.json` 事實表全文、最新一季逐字稿全文、判斷卡（`judge_card.md`）、常載附卡（ROIC 持續期檢核、情境判斷問題字典）、archetype 命中時的條件附卡、前份判斷摘要，最後是回覆格式規範。bundle 之外一律不存在：不讀 `docs/dd/` 任何既有報告，不查證任何未附上的資料，不重述 bundle 內容。

## 三條在動筆前先掃一遍的硬規則

1. **負向證據強制處置**——`facts.json` 的 `findings_digest[]` 內每一條 `direction="-"` 的 finding，必須落在 `counter_evidence.contradictions[]`／`blind_spots[]`／`triggers[]`／`answers.q2_moat` 內 `moat.threats[]`／`thesis.R[]` 之一的 `evidence_refs`，或寫進 `counter_evidence.evidence_dismissed[]`（`{"ref": …, "reason": …}`，理由要指得出證據本身的問題，不得寫「影響不大」）。
2. **引用可追溯**——事實表已有的資料用該題 `fact_refs[]`；索引漏收時可在理由中引用本包原始證據，寫明欄位路徑、來源與期間。不得捏造 `f_*` id，不得從記憶補數字，原始證據也沒有才標資料缺口。
3. **前份漂移按原因分組**——前份判斷摘要裡有變動的每一欄都要映射到 `counter_evidence.contradictions[]` 一條帶 `cause`（`價格變動`／`新證據`／`方法變動`）的條目，漏一欄視為未處理；行動門檻（`kill_metrics`／`triggers` 的門檻數字、Single Thing）與前份不同時必歸因，`rearm_trigger` 不得對已變動的門檻寫「相同」。

## 禁

- 不自搜補洞：證據不足就在對應欄位標「事實表未涵蓋」。
- 不引用 bundle 之外的任何資料。
- enum 欄位只准用速查列出的值，不得自行加註解或譯成中文；`kill_metrics[]` 是陣列不是索引鍵物件；§5.R 四檢查點四項必答（缺一即無效）。


===== BUNDLE =====

## ② Schema 速查（judge-owned 形狀；機械生成自 judgment.schema.json 的 v19_contract 區塊）

格式：縮排＝巢狀層級（不重複完整路徑）；行首 `*`＝必填；型別簡寫 str/obj/arr/int/num/bool，`a|b`＝可為多型別（含 null）；`enum[...]`＝允許值；`pat=`＝正則；`≤N`＝maxLength；`≥N`＝minItems；陣列欄位以 `key[]` 表示，其元素（items）型別接在同一行，物件元素的欄位在下一層縮排列出。

*meta
  *ticker: str
  *date: str pat=^\d{4}-\d{2}-\d{2}$
  *schema: str pat=^v1[2345]\.\d+$
  *contract: str enum[v19]
  company_name: str|null
*oneliner: str ≤200
*facts_ref: str
*scenario_ref: str|null
*answers
  *q1_business
    *verdict: str
    *reasoning: str
    *fact_refs[]: arr str pat=^f_[a-z0-9_]+$
    *verdict_values
      *revenue_quality: str|null
      *unit_econ_note: str|null
      *archetype
        *primary: str|null
        secondary: str|null
        confidence: str|null
        fingerprint: str|null
      *industry
        *clock_phase: str|null enum[I｜II｜III｜IV｜None]
        *sd_verdict_source: str|null
        bargaining
          up: str|null
          down: str|null
          geo: str|null
        profit_pool_dir: str|null
        *tam_table: arr|obj
      single_thing
  *q2_moat
    *verdict: str
    *reasoning: str
    *fact_refs[]: arr str pat=^f_[a-z0-9_]+$
    *verdict_values
      *moat
        *mechanism: str|null
        *execution: num|null
        *pricing: num|null
        combined: num|null
        score: num|null
        *grade: str|null enum[S｜A｜B｜C｜X｜None]
        *trend: str|null enum[↑｜→｜↓｜None]
        *trend_evidence: str|null
        *competitor_notes[]: arr
          *name: str
          *strategy_note: str
        spread_notes: obj|null
        peer_na_reason: str|null
        *threats[]: arr
          level: str|null
          text: str|null
          p: str|num|null
          evidence_refs[]: arr str
        *roic_durability
          quadrant: str|null
          *checkpoints[]: arr
          *roiic: num|str|null
          *reinvest_rate: num|str|null
          *endo_ceiling: num|null
          formula_note: str|null
  *q3_growth
    *verdict: str
    *reasoning: str
    *fact_refs[]: arr str pat=^f_[a-z0-9_]+$
    *verdict_values
      *growth
        *driver_mix: str|null
        runway_years: num|str|null
        *runway_post_y5: str|null enum[🟢｜🟡｜🔴｜None]
        *endo_ceiling_basis: str|null
        *segments: arr|obj
        seven_questions[]: arr
        decay_signals[]: arr
        trap_rating: str|null
  *q4_capital
    *verdict: str
    *reasoning: str
    *fact_refs[]: arr str pat=^f_[a-z0-9_]+$
    *verdict_values
      *capalloc
        *items[]: arr ≥1
          *name: str enum[ma_roiic｜buyback_yield｜sbc_dilution]
          *applicable: bool|null
          *passed: bool|null
          *input: str|null
        grade: str|null enum[A｜B｜C｜None]
      *governance
        *capital_returns: arr|obj
        scorecard[]: arr
        sbc
      quality
        three_year[]: arr
        dupont[]: arr ≥1
        ccc[]: arr ≥1
        buyback
        lumpiness
        financial_note: str
        latest_quarter_note: str
  *q5_valuation
    *verdict: str
    *reasoning: str
    *fact_refs[]: arr str pat=^f_[a-z0-9_]+$
    *verdict_values
      *valuation
        *basis: str|null
        tier: str|null
        *peers: arr|obj
        fwd_pe: num|null
        *peg: num|null
        *percentile_5y: num|null
        *val_light: str|null enum[🟢｜🟡｜🟠｜🔴｜None]
        *val_light_derivation: str|null
        targets
        *upside_short_pct: num|null
        *upside_mid_pct: num|null
        *denominator_disputed: bool|null
        *denominator_note: str|null
  *q6_how_wrong
    *verdict: str
    *reasoning: str
    *fact_refs[]: arr str pat=^f_[a-z0-9_]+$
    *verdict_values
      *trap
        *verdict: str|null enum[🟢｜🟡｜🔴｜None]
        *label: str|null
*scenario_inputs
  *terminal_label: str
  start
  valuation_basis: str|null enum[eps_pe｜sales_multiple｜None]
  rev
    bull[]: arr ≥1 num
    base[]: arr ≥1 num
    bear[]: arr ≥1 num
  ev_s
    bull: num|null
    base: num|null
    bear: num|null
  net_debt_y5
    bull: num|null
    base: num|null
    bear: num|null
  shares_y5
    bull: num|null
    base: num|null
    bear: num|null
  eps
    *bull[]: arr ≥1 num
    *base[]: arr ≥1 num
    *bear[]: arr ≥1 num
  pe
    *bull: num|null
    *base: num|null
    *bear: num|null
  *p
    *bull: num|null
    *base: num|null
    *bear: num|null
  yield_pct
  second_stage
  basis
  endo_ceiling_exceeded: bool|null
  peer_max_fpe: num|null
  *max_dd
    *lo: num|null
    *hi: num|null
    *basis: str|null
    trigger_time: str|null
*counter_evidence
  *blind_spots[]: arr ≥1
    view: str|null enum[論點失敗｜論點成功但股東經濟變差｜價格已反映太多｜None]
    evidence: str|null
    assumption: str|null
    consequence: str|null
    ruling: str|null
    watch: str|null
    not_applicable_reason: str|null
    evidence_refs[]: arr str
    fact_refs[]: arr str
  *contradictions[]: arr
    axis: str|null
    cause: str|null enum[價格變動｜新證據｜方法變動｜None]
    prior_field: str|arr|null
    side_a: str|null
    side_b: str|null
    ruling: str|null
    evidence_level: str|null
    settle_metric: str|null
    if_then[]: arr str
    evidence_refs[]: arr str
  *triggers[]: arr ≥1
    *n: int|str
    *text: str|null
    *type: str|null enum[假設驗證｜風險｜Single Thing｜估值rearm｜加碼｜減碼｜清倉｜複審日期｜None]
    *maps_to: str|null
    *metric: str|null
    *threshold: str|null
    *action: str|null
    *source_freq: str|null
    *date: str|null
    type_display: str|null
    evidence_refs[]: arr str
  kill_metrics[]: arr
    *metric: str|null ≤120
    *bear_threshold: str|null ≤120
    *window: str|null ≤60
    source: str|null ≤120
    last_status: str|null enum[ok｜warning｜triggered｜unknown｜None]
  evidence_dismissed[]: arr
    ref: str|null
    reason: str|null
  *action_conditions
    *rearm_trigger: str|null ≤120
    *exec_line: str|null
    holding_cap: str|null
*decision_inputs
  *signal: str|null enum[A+｜A｜B｜C｜X｜None]
  *ma: str|null enum[🟢｜✅｜🟡｜🟠｜❌｜-｜None]
  *cycle_position: str|null
  *cycle_verdict: str|null
  *thesis_irreconcilable: bool|null
  *valuation_dependent: bool|null
  *market_wrong_reason_given: bool|str|null
  *momentum_overheated: bool|null
  *cycle_gates_pass: bool|null
  qc49_inherit_prior: bool|null
  wait_for_price: bool|null
  wait_for_price_condition: str|null
  qc48_result: str|null enum[pass｜fail｜not_run｜None]
  qc48_note: str|null
*decision_out
  *verdict: str|null
  *role: str|null
  *row_hit: str|null
  pacing[]: arr str
  holding_cap: str|null
  requires_critic[]: arr str
  *audit_rows[]: arr str|obj
*thesis
  *H[]: arr ≥3
    *id: str pat=^H[1-9][0-9]*$
    *text: str|null
    2y: str|null
    5y: str|null
    10y: str|null
    *threshold: str|null
    *source: str|null
    *drift_rule: str|null
  *R[]: arr ≥3
    *id: str pat=^R[1-9][0-9]*$
    *text: str|null
    *h_ref: str|null
    *clock: str|null enum[⚡｜🔥｜🐢｜None]
    *threshold: str|null
    evidence_refs[]: arr str
  *single_thing
    *description: str|null
    *why_fatal: str|null
    *if_happens: str|null
    *how_monitor: str|null
    *probability: str|null
*appendix_a
  *growth_durability: num|null
  *quality_score: num|null
  *ai_risk: str|null enum[🟢｜🟡｜🔴｜None]
  *long_term_confidence: str|null enum[高｜中｜低｜None]
  *fpe_fy2: num|null
  *peg_fy2: num|null
  *stress
    *pass: int|null
    *total: int|null
*eps_meta
  *base_eps_path
  fy_end_month: int|null
  eps_basis: str|null
catalysts[]: arr
  *date: str|null
  date_precision: str|null enum[month｜quarter｜None]
  *type: str|null enum[product｜regulatory｜capacity｜guidance｜macro｜other｜None]
  *event: str|null
  *impact: str|null enum[高｜中｜低｜None]
  *watch: str|null

### evidence_refs 用法（v19）
`counter_evidence.contradictions[]`／`counter_evidence.blind_spots[]`／`counter_evidence.triggers[]`／`answers.q2_moat.verdict_values.moat.threats[]`／`thesis.R[]` 可各自加選填 `evidence_refs: [string]`，格式 `axis_id#index`（對應事實表 `findings_digest[]` 的 `id`）。無法對應到既有證據、但仍要捨棄的負向 finding，記到 `counter_evidence.evidence_dismissed: [{ref, reason}]`（理由要指得出證據本身的問題，不得寫「影響不大」）。`validate_judgment.py --evidence`（J1）會檢查每條 `direction=="-"` 的 finding 是否被上述任一處引用，未引用＝FAIL。

### fact_refs 用法（v19）
`answers.qX.fact_refs[]` 只准填事實表裡真的存在的 `f_*` id（引不到＝FAIL）。索引漏收時可引用本包原始證據，寫明欄位路徑、來源與期間；不要捏造 fact id，也不要從記憶補數字。

### 不要填的欄（填了即 FAIL）
`decision_inputs` 的 `trap`、`val`、`moat`、`moat_trend`、`runway_post_y5`、`capalloc_grade`、`archetype`、`price_at_dd`、`week26_return_pct`、`consensus_rev_3m_pct`、`asym_ratio`、`irr_base_pct`、`ev5y_pct`、`val_denominator_disputed`、`val_denominator_note` 一律留 `null` 或整個不寫——由程式從六問答案與事實表投影。同理不要寫 `moat.spread_table`／`moat.competitors`（同業數字在事實表的 `peer_comparison`，你只寫 `moat.competitor_notes` 每家一句判讀）、`reasoning`／`plain`／`contradictions` 等舊形狀頂層欄、以及整份 `scenario.json`。

### §5.R 四檢查點形狀（checkpoints[] 未在上方展開，這裡手動點名）
`answers.q2_moat.verdict_values.moat.roic_durability.checkpoints[]` 四項（需求基礎值／決策層級／價值鏈分配／社會容忍度）**每項各一筆物件**，鍵名固定 `item`（四項名稱之一，逐字比對，不得改寫或縮寫）／`level`（🟢🟡🔴）／`text`（判讀句；查無或不適用改填 `not_applicable_reason`）。四項缺一，或某項 `text` 與 `not_applicable_reason` 皆空＝FAIL（`validate_judgment.v19_required_items_checks`）。

### kill_metrics[] 形狀（counter_evidence.kill_metrics，未在上方展開，這裡手動點名）
是**陣列**（`[{...}, {...}]`），不是以索引數字（`"0"`／`"1"`）當鍵的物件；每條必填 `metric`／`bear_threshold`／`window`，並附 `source`（資料來源）。

### 機器語言／半形標點洩漏詞表（單一權威：`dd_sections.LEAK_PATTERNS` ＋ `qc.CJK_PUNCT_RE`）
`row ?\d`、`Hard Veto`、`Soft Veto`、`signal ?[ABCX]\b`、`估值燈`、`val ?[🟢🟡🟠🔴]`、`MA ?[✅❌🟢🟡🟠]`、`Pure MA`、`盲點 ?\d`、`PREREG`、`dd-meta`、`runway_post_y5`、`capalloc`、`QC-\d`、`archetype`、`metadata`、`硬接線`、`接線[:：]`、`Guardrail`、`校驗紀錄`、`判定規則`、`\bgate\b`、`\bF2\b`、`row 8[ab]`、`爆發候選路徑`、`循環衛星進場路徑`
- CJK 字元後接半形 `,` `.` `:`（正則 `[㐀-䶿一-鿿豈-﫿][,.:]`）——一律應為全形 ，。：

---

## ②b enum 表（機械抽自 judgment.schema.json；這些欄只准填表列值，填自由文字＝FAIL）

- `answers.q1_business.verdict_values.industry.clock_phase`：I｜II｜III｜IV
- `answers.q2_moat.verdict_values.moat.grade`：S｜A｜B｜C｜X
- `answers.q2_moat.verdict_values.moat.trend`：↑｜→｜↓
- `answers.q3_growth.verdict_values.growth.runway_post_y5`：🟢｜🟡｜🔴
- `answers.q4_capital.verdict_values.capalloc.items[].name`：ma_roiic｜buyback_yield｜sbc_dilution
- `answers.q4_capital.verdict_values.capalloc.grade`：A｜B｜C
- `answers.q5_valuation.verdict_values.valuation.val_light`：🟢｜🟡｜🟠｜🔴
- `answers.q6_how_wrong.verdict_values.trap.verdict`：🟢｜🟡｜🔴
- `scenario_inputs.valuation_basis`：eps_pe｜sales_multiple
- `counter_evidence.blind_spots[].view`：論點失敗｜論點成功但股東經濟變差｜價格已反映太多
- `decision_inputs.signal`：A+｜A｜B｜C｜X
- `decision_inputs.ma`：🟢｜✅｜🟡｜🟠｜❌｜-
- `decision_inputs.qc48_result`：pass｜fail｜not_run
- `appendix_a.ai_risk`：🟢｜🟡｜🔴
- `appendix_a.long_term_confidence`：高｜中｜低
- `archetype.primary（投影後驗）`：品質複利成長｜循環/商品｜金融｜未獲利高成長｜轉機/特殊情境｜受監管公用/穩定內需｜EMS/ODM
- `archetype.confidence（投影後驗）`：高｜中｜低
- `decision_inputs.trap（投影後驗）`：🟢｜🟡｜🔴
- `decision_inputs.val（投影後驗）`：🟢｜🟡｜🟠｜🔴
- `decision_inputs.moat_trend（投影後驗）`：↑｜→｜↓
- `decision_inputs.moat（投影後驗）`：S｜A｜B｜C｜X
- `decision_inputs.capalloc_grade（投影後驗）`：A｜B｜C
- `decision_inputs.archetype（投影後驗）`：品質複利成長｜循環/商品｜金融｜未獲利高成長｜轉機/特殊情境｜受監管公用/穩定內需｜EMS/ODM
- `decision_inputs.cycle_position（投影後驗）`：深谷投降｜早循環｜中循環｜晚循環｜過熱頂部
- `decision_inputs.cycle_verdict（投影後驗）`：右側可追蹤｜等回踩｜頂部觀望｜未觸發
- `triggers[].type（投影後驗）`：假設驗證｜風險｜Single Thing｜估值rearm｜加碼｜減碼｜清倉｜複審日期
- `catalysts[].date_precision（投影後驗）`：month｜quarter
- `catalysts[].impact（投影後驗）`：高｜中｜低
- `thesis.R[].clock（投影後驗）`：⚡｜🔥｜🐢

---

## ②c 理由文字禁用詞表（QC-40 機器語言，命中任一＝FAIL；這些是給程式看的代號，不是給讀者的話）

以下為 regex 原文，逐條避開（含變體）：

`row ?\d`　`Hard Veto`　`Soft Veto`　`signal ?[ABCX]\b`　`估值燈`　`val ?[🟢🟡🟠🔴]`　`MA ?[✅❌🟢🟡🟠]`　`Pure MA`　`盲點 ?\d`　`PREREG`　`dd-meta`　`runway_post_y5`　`capalloc`　`QC-\d`　`archetype`　`metadata`　`硬接線`　`接線[:：]`　`Guardrail`　`校驗紀錄`　`判定規則`　`\bgate\b`　`\bF2\b`　`row 8[ab]`　`爆發候選路徑`　`循環衛星進場路徑`

改寫原則：說結論本身，不說「燈號／閘／row／QC／驗算」這類流程代號。例：「估值燈色不變」→「估值結論不變」；「row 8a」→ 直接寫進場條件本身，不用路徑代號。

---

## ③ facts.json 事實表全文（引用索引；含 findings_digest 與同業對照）

（以下 JSON 為緊湊格式（省空白），內容完整）
```json
{"meta":{"ticker":"CVS","date":"2026-11-08","schema":"facts-v1","generator":"dd_facts.py extract（零 LLM；needs_sonnet 題目待事實表 agent 補）","evidence_ref":"/Users/ivanchang/financial-analysis-bot/.dd_build/runs/CVS_20261108/evidence.json","digest_ref":"/Users/ivanchang/financial-analysis-bot/.dd_build/runs/CVS_20261108/digest.json"},"questions":{"q1_business":{"label":"怎麼賺錢","facts":[{"id":"f_kpi0_total_revenues_gaap","label":"Total revenues (GAAP)","value":108.399,"period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"USD bn","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[0]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_kpi1_adjusted_operating_incom","label":"Adjusted operating income / margin (non-GAAP)","value":4.194,"period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"USD bn（利益率 3.87%）","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[1]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_kpi2_gaap_operating_income_ma","label":"GAAP operating income / margin","value":3.566,"period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"USD bn（利益率 3.29%）","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[2]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_kpi3_gaap_diluted_eps","label":"GAAP diluted EPS","value":1.68,"period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"USD","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[3]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_kpi4_adjusted_eps","label":"Adjusted EPS","value":2.09,"period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"USD","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[4]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_kpi7_medical_benefit_ratio_mb","label":"Medical benefit ratio (MBR)","value":91.3,"period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"%","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[7]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_kpi8_management_guidance_fy20","label":"Management guidance FY2026（2026-11-04 上調）","value":"Adj EPS ≥ 8.20；GAAP EPS ≥ 6.98；營運現金流 ≥ 15.5bn；營收 ≥ 420.0bn","period":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","unit":"USD","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"guidance","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[8]","as_of":"Q3 FY2026（季末 2026-09-30，公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html"}},{"id":"f_earnings_recency","label":"最近一次財報日","value":"2026-11-04","period":"2026-11-04","unit":"date","basis":"距今 3 個交易日","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.earnings_recency","as_of":"2026-11-04"}}],"needs_sonnet":true,"needs_sonnet_note":"分部與客戶占比、單價與量的結構化值、商業模式收錢方式——evidence.numbers 無此欄位，須由事實表 agent 從 10-K／10-Q／逐字稿補。"},"q2_moat":{"label":"競爭優勢","facts":[{"id":"f_peer_cvs_gross_margin_pct","label":"CVS 毛利率","value":14.23,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CVS.gross_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_cvs_operating_margin_pct","label":"CVS 營業利益率","value":3.58,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CVS.operating_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_cvs_fcf_margin_pct","label":"CVS FCF 利潤率","value":3.7,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CVS.fcf_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_ci_gross_margin_pct","label":"CI 毛利率","value":8.79,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CI.gross_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_ci_operating_margin_pct","label":"CI 營業利益率","value":3.1,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CI.operating_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_ci_fcf_margin_pct","label":"CI FCF 利潤率","value":2.82,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CI.fcf_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_unh_gross_margin_pct","label":"UNH 毛利率","value":19.84,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.UNH.gross_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_unh_operating_margin_pct","label":"UNH 營業利益率","value":5.32,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.UNH.operating_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_unh_fcf_margin_pct","label":"UNH FCF 利潤率","value":5.08,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.UNH.fcf_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_elv_fcf_margin_pct","label":"ELV FCF 利潤率","value":3.23,"period":"TTM ending 2026-09-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.ELV.fcf_margin_pct","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"id":"f_peer_hum_fcf_margin_pct","label":"HUM FCF 利潤率","value":1.34,"period":"TTM ending 2026-06-30（4季加總）","unit":"%","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.peer_financials.HUM.fcf_margin_pct","as_of":"TTM ending 2026-06-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"}],"needs_sonnet":true,"needs_sonnet_note":"護城河機制的量化證據（份額、轉換成本、ROIC 輸入的投入資本口徑）——numbers.peer_financials 只給同業利潤率，其餘須補。"},"q3_growth":{"label":"成長","facts":[],"needs_sonnet":true,"needs_sonnet_note":"TAM 與滲透率、在手訂單、分部三年成長——evidence.numbers 無此欄位，須補；共識三年 EPS 已由 q5 的共識修正條目帶入，成長題引用同一組 id 不重收。"},"q4_capital":{"label":"現金與資本配置","facts":[{"id":"f_kpi5_free_cash_flow_ytd","label":"Free cash flow（YTD，營運現金流 − 資本支出）","value":12.961,"period":"前九個月 YTD 至 2026-09-30（公告於 2026-11-04）；單季 FCF 新聞稿未列","unit":"USD bn","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[5]","as_of":"前九個月 YTD 至 2026-09-30（公告於 2026-11-04）；單季 FCF 新聞稿未列","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html（現金流量表：營運現金流 15,318 − 購置不動產設備 2,357，百萬美元）"}},{"id":"f_kpi6_sbc_ytd","label":"SBC 占營業利益（YTD）","value":4.2,"period":"前九個月 YTD 至 2026-09-30（公告於 2026-11-04）","unit":"% of adjusted operating income（占 GAAP 營業利益 4.7%）","basis":"evidence.numbers.latest_quarter_kpis 逐項口徑照抄（metric 名稱即口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.latest_quarter_kpis.items[6]","as_of":"前九個月 YTD 至 2026-09-30（公告於 2026-11-04）","citation":"CVS 公司 IR 新聞稿（Exhibit 99.1，2026-11-04）https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html（SBC 610 百萬 ÷ 調整後營業利益 14,501；GAAP 12,949）"}}],"needs_sonnet":true,"needs_sonnet_note":"近三年現金去向四分、債務到期結構與加權平均利率、回購均價——numbers 只有最新一季 KPI，其餘須補。"},"q5_valuation":{"label":"估值","facts":[{"id":"f_price_at_dd","label":"判斷日股價","value":83.85,"period":"2026-11-06（RTH 收盤，UTC）","unit":"USD","basis":"收盤價，與情境樹起點同源","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.price_at_dd","as_of":"2026-11-06（RTH 收盤，UTC）"}},{"id":"f_week26_return_pct","label":"26 週報酬","value":-6.16,"period":"2026-11-06（RTH 收盤，UTC）","unit":"%","basis":"含息前價格報酬，對照基準 ^GSPC","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.momentum_26w.return_26w_pct","as_of":"2026-11-06（RTH 收盤，UTC）"}},{"id":"f_rsi14","label":"RSI(14)","value":40.49,"period":"2026-11-06（RTH 收盤，UTC）","unit":"","basis":"日線 14 期；rsi14_usable=True","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.momentum_26w.rsi14","as_of":"2026-11-06（RTH 收盤，UTC）"}},{"id":"f_consensus_rev_fy1_pct","label":"FY1 共識修正","value":0.0,"period":"2026-11-07","unit":"%","basis":"兩份 Koyfin 快照之間的 EPS 修正幅度（8.04 → 8.04）","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.fy1.revision_pct","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_consensus_rev_fy2_pct","label":"FY2 共識修正","value":0.0,"period":"2026-11-07","unit":"%","basis":"兩份 Koyfin 快照之間的 EPS 修正幅度（8.54 → 8.54）","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.fy2.revision_pct","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_consensus_rev_fy3_pct","label":"FY3 共識修正","value":0.0,"period":"2026-11-07","unit":"%","basis":"兩份 Koyfin 快照之間的 EPS 修正幅度（9.69 → 9.69）","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.fy3.revision_pct","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_consensus_eps_fy1","label":"FY1 共識 EPS","value":8.04,"period":"2026-11-07","unit":"USD/share","basis":"Koyfin 快照共識值；財年口徑見判斷檔 eps_meta.eps_basis","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.latest_snapshot.fy1","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_consensus_eps_fy2","label":"FY2 共識 EPS","value":8.54,"period":"2026-11-07","unit":"USD/share","basis":"Koyfin 快照共識值；財年口徑見判斷檔 eps_meta.eps_basis","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.latest_snapshot.fy2","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_consensus_eps_fy3","label":"FY3 共識 EPS","value":9.69,"period":"2026-11-07","unit":"USD/share","basis":"Koyfin 快照共識值；財年口徑見判斷檔 eps_meta.eps_basis","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.latest_snapshot.fy3","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_consensus_rev_3m_fy1_pct","label":"FY1 共識近 3 個月修正","value":1.39,"period":"2026-08-13 → 2026-11-07","unit":"%","basis":"FY1 共識 EPS 7.93 → 8.04（Koyfin 快照，約 90 天間距）；投影成 decision_inputs.consensus_rev_3m_pct","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.consensus_revision.latest_snapshot.fy1 ÷ snapshot_90d_prior.fy1","as_of":"2026-11-07","citation":"DD_universe_EPS_estimates_20261107.xlsx"}},{"id":"f_pe_current","label":"Trailing P/E（現值）","value":9.74,"period":"2026-11-06（RTH 收盤，UTC）","unit":"x","basis":"4 個年度端點內的分位＝0.0","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.trailing.pe","as_of":"2026-11-06（RTH 收盤，UTC）","citation":"trailing 口徑：以年度財報 fiscal-year-end 對應最近週線收盤價，逐年估算 trailing P/E／P/S／EV/S（yfinance 免費層年度財報僅回溯 4-5 年，非連續日頻 5 年序列——樣本點數見各子欄 n_points）。fwd_recent_window 另用本站 data/eps-estimates/ 月度快照 archive（現存約 2026-05 起）算一段短窗真 fwd PE，非 5 年歷史，勿與 trailing 混用。"}},{"id":"f_pe_percentile","label":"Trailing P/E 年度端點分位","value":0.0,"period":"2026-11-06（RTH 收盤，UTC）","unit":"%","basis":"**非五年分位**：只用 4 個年度端點，valuation.percentile_5y 另有口徑","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.trailing.pe.current_percentile_within_annual_points","as_of":"2026-11-06（RTH 收盤，UTC）"}},{"id":"f_ps_current","label":"P/S（現值）","value":0.26,"period":"2026-11-06（RTH 收盤，UTC）","unit":"x","basis":"4 個年度端點內的分位＝61.3","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.trailing.ps","as_of":"2026-11-06（RTH 收盤，UTC）","citation":"trailing 口徑：以年度財報 fiscal-year-end 對應最近週線收盤價，逐年估算 trailing P/E／P/S／EV/S（yfinance 免費層年度財報僅回溯 4-5 年，非連續日頻 5 年序列——樣本點數見各子欄 n_points）。fwd_recent_window 另用本站 data/eps-estimates/ 月度快照 archive（現存約 2026-05 起）算一段短窗真 fwd PE，非 5 年歷史，勿與 trailing 混用。"}},{"id":"f_ps_percentile","label":"P/S 年度端點分位","value":61.3,"period":"2026-11-06（RTH 收盤，UTC）","unit":"%","basis":"**非五年分位**：只用 4 個年度端點，valuation.percentile_5y 另有口徑","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.trailing.ps.current_percentile_within_annual_points","as_of":"2026-11-06（RTH 收盤，UTC）"}},{"id":"f_ev_s_current","label":"EV/S（現值）","value":0.4,"period":"2026-11-06（RTH 收盤，UTC）","unit":"x","basis":"4 個年度端點內的分位＝38.1","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.trailing.ev_s","as_of":"2026-11-06（RTH 收盤，UTC）","citation":"trailing 口徑：以年度財報 fiscal-year-end 對應最近週線收盤價，逐年估算 trailing P/E／P/S／EV/S（yfinance 免費層年度財報僅回溯 4-5 年，非連續日頻 5 年序列——樣本點數見各子欄 n_points）。fwd_recent_window 另用本站 data/eps-estimates/ 月度快照 archive（現存約 2026-05 起）算一段短窗真 fwd PE，非 5 年歷史，勿與 trailing 混用。"}},{"id":"f_ev_s_percentile","label":"EV/S 年度端點分位","value":38.1,"period":"2026-11-06（RTH 收盤，UTC）","unit":"%","basis":"**非五年分位**：只用 4 個年度端點，valuation.percentile_5y 另有口徑","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.trailing.ev_s.current_percentile_within_annual_points","as_of":"2026-11-06（RTH 收盤，UTC）"}},{"id":"f_fwd_pe_latest","label":"Forward P/E（最近快照）","value":10.43,"period":"2026-11-07","unit":"x","basis":"分母＝FY1 EPS 8.04，分子＝快照價 83.85","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.valuation_history.fwd_recent_window.points[-1]","as_of":"2026-11-07"}},{"id":"f_dividend_yield_ttm","label":"trailing 12個月股息殖利率","value":3.172,"period":"2026-11-08","unit":"%","basis":"trailing 12個月股息（依除息日加總，非發放日）÷ 判斷日股價 × 100","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.dividend_yield_ttm.value_pct","as_of":"2026-11-08"}},{"id":"f_net_debt_m","label":"目前淨負債（總債務－現金及短投）","value":60410.0,"period":"2026-11-08","unit":"USD m","basis":"yfinance 最新一季：總債務 75297.0、現金 14887.0（含租賃負債口徑）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.capital_structure.net_debt_m","as_of":"2026-11-08"},"note":"股數＝目前流通股數（各類股合計）或最新季稀釋均股，未含未行使選擇權／可轉債的完整稀釋，終端股數的稀釋由判斷者在 shares_y5 自行反映；共識營收 FY3：yfinance 只有 0y／+1y 兩個年度，無第三年，留 null"},{"id":"f_shares_diluted_m","label":"目前股數（百萬股）","value":1279.47,"period":"2026-11-08","unit":"m shares","basis":"yfinance impliedSharesOutstanding（各類股合計）","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.capital_structure.shares_diluted_m","as_of":"2026-11-08"},"note":"股數＝目前流通股數（各類股合計）或最新季稀釋均股，未含未行使選擇權／可轉債的完整稀釋，終端股數的稀釋由判斷者在 shares_y5 自行反映；共識營收 FY3：yfinance 只有 0y／+1y 兩個年度，無第三年，留 null"},{"id":"f_ev_m","label":"目前企業價值 EV（市值＋淨負債）","value":167693.91,"period":"2026-11-08","unit":"USD m","basis":"市值 107283.91 ＋ 淨負債 60410.0","kind":"realized","source":{"type":"evidence_numbers","ref":"numbers.capital_structure.ev_m","as_of":"2026-11-08"},"note":"股數＝目前流通股數（各類股合計）或最新季稀釋均股，未含未行使選擇權／可轉債的完整稀釋，終端股數的稀釋由判斷者在 shares_y5 自行反映；共識營收 FY3：yfinance 只有 0y／+1y 兩個年度，無第三年，留 null"},{"id":"f_rev_consensus_fy1_m","label":"FY1 共識營收（百萬）","value":422701.67,"period":"2026-11-08","unit":"USD m","basis":"yfinance revenue_estimate 0y 平均（12 位分析師）；與 f_consensus_eps_fy1 同一財年","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.capital_structure.revenue_consensus.fy1.avg_m","as_of":"2026-11-08"},"note":"股數＝目前流通股數（各類股合計）或最新季稀釋均股，未含未行使選擇權／可轉債的完整稀釋，終端股數的稀釋由判斷者在 shares_y5 自行反映；共識營收 FY3：yfinance 只有 0y／+1y 兩個年度，無第三年，留 null"},{"id":"f_rev_consensus_fy2_m","label":"FY2 共識營收（百萬）","value":431108.6,"period":"2026-11-08","unit":"USD m","basis":"yfinance revenue_estimate +1y 平均（21 位分析師）；與 f_consensus_eps_fy2 同一財年","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.capital_structure.revenue_consensus.fy2.avg_m","as_of":"2026-11-08"},"note":"股數＝目前流通股數（各類股合計）或最新季稀釋均股，未含未行使選擇權／可轉債的完整稀釋，終端股數的稀釋由判斷者在 shares_y5 自行反映；共識營收 FY3：yfinance 只有 0y／+1y 兩個年度，無第三年，留 null"},{"id":"f_ev_s_fwd","label":"EV/S（EV ÷ FY1 共識營收）","value":0.4,"period":"2026-11-08","unit":"x","basis":"f_ev_m ÷ f_rev_consensus_fy1_m（前瞻口徑；f_ev_s_current 是 trailing 12 個月營收口徑）","kind":"estimate","source":{"type":"evidence_numbers","ref":"numbers.capital_structure.ev_m ÷ revenue_consensus.fy1.avg_m","as_of":"2026-11-08"},"note":"股數＝目前流通股數（各類股合計）或最新季稀釋均股，未含未行使選擇權／可轉債的完整稀釋，終端股數的稀釋由判斷者在 shares_y5 自行反映；共識營收 FY3：yfinance 只有 0y／+1y 兩個年度，無第三年，留 null"},{"id":"f_ma_state","label":"週線均線六態（decision_inputs.ma 必須等於此值）","value":"🟡","period":"2026-11-08","unit":null,"basis":"timing-appendix §F 週線六態：🟢 價<W52且>W104且三斜率正｜✅ 價>W52>W104>W250且W250斜率>+3%｜🟡 排列過但W250斜率−3~+3%｜🟠 價<W104但>W250｜❌ 價<W250或斜率<−3%","kind":"realized","source":{"type":"manual","ref":"ma_snapshot.json","as_of":"2026-11-08","citation":"程式計算：dd_screener_ma.compute_ma_snapshot（yfinance 週線收盤，W52/W104/W250 SMA，W250 斜率＝13 週變化）"},"quote":"price 83.85 / W52 85.66 / W104 73.57 / W250 71.46 / W250 13週斜率 0.04%"},{"id":"f_ma_w52","label":"52 週均線","value":85.66,"period":"2026-11-08","unit":"USD","basis":"週線收盤 SMA（yfinance auto_adjust）","kind":"realized","source":{"type":"manual","ref":"ma_snapshot.json","as_of":"2026-11-08","citation":"程式計算：dd_screener_ma.compute_ma_snapshot（yfinance 週線收盤，W52/W104/W250 SMA，W250 斜率＝13 週變化）"}},{"id":"f_ma_w104","label":"104 週均線","value":73.57,"period":"2026-11-08","unit":"USD","basis":"週線收盤 SMA（yfinance auto_adjust）","kind":"realized","source":{"type":"manual","ref":"ma_snapshot.json","as_of":"2026-11-08","citation":"程式計算：dd_screener_ma.compute_ma_snapshot（yfinance 週線收盤，W52/W104/W250 SMA，W250 斜率＝13 週變化）"}},{"id":"f_ma_w250","label":"250 週均線","value":71.46,"period":"2026-11-08","unit":"USD","basis":"週線收盤 SMA（yfinance auto_adjust）","kind":"realized","source":{"type":"manual","ref":"ma_snapshot.json","as_of":"2026-11-08","citation":"程式計算：dd_screener_ma.compute_ma_snapshot（yfinance 週線收盤，W52/W104/W250 SMA，W250 斜率＝13 週變化）"}},{"id":"f_ma_slope_w250_pct","label":"W250 13 週斜率","value":0.04,"period":"2026-11-08","unit":"%","basis":"週線收盤 SMA（yfinance auto_adjust）","kind":"realized","source":{"type":"manual","ref":"ma_snapshot.json","as_of":"2026-11-08","citation":"程式計算：dd_screener_ma.compute_ma_snapshot（yfinance 週線收盤，W52/W104/W250 SMA，W250 斜率＝13 週變化）"}}],"needs_sonnet":true,"needs_sonnet_note":"同業倍數對照與目標價（若承重）——其餘估值事實已機械抽出。"},"q6_how_wrong":{"label":"可能看錯在哪","facts":[],"needs_sonnet":true,"needs_sonnet_note":"歷史最大回撤幅度、空方最強數字、訴訟與監管的金額與時點——須由事實表 agent 從 findings_digest 與 filing 補。"}},"findings_digest":[{"id":"competitive_share_entrants#0","axis":"competitive_share_entrants","section":"coverage","direction":"-","claim":"10-K 稱健康福利業新進入者與產業整併加劇競爭，新興對手含新創health plan、醫院自有health plan、合資、金融／顧問公司私有交易所及零售業等非傳統通路","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"New entrants into the marketplace, as well as consolidation within the industry, have contributed to and are expected to intensify the competitive environment.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["moat_trend","decision_inputs.bear"],"status":"ok"},{"id":"competitive_share_entrants#1","axis":"competitive_share_entrants","section":"coverage","direction":"0","claim":"10-K 列示PBM主要對手：Prime Therapeutics、MedImpact、Express Scripts(Cigna)、Optum Rx(UnitedHealth)及獨立PBM；零售藥局對手含Walgreens、Walmart、Amazon","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"The Health Services segment has a significant number of competitors offering PBM services, including large, national PBM companies (e.g., Prime Therapeutics and MedImpact), PBMs owned by large national health plans (e.g., the Express Scripts business of Cigna Corporation and the Optum Rx business of UnitedHealth Group) and smaller standalone PBMs.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"competitive_share_entrants#2","axis":"competitive_share_entrants","section":"coverage","direction":"-","claim":"Aetna 退出2026年ACA個人保險交易所","source":"Fierce Healthcare: Aetna to exit the ACA exchanges in 2026","url":"https://www.fiercehealthcare.com/payers/aetna-exit-aca-exchanges-2026","excerpt":null,"as_of":"2025-05-01","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"competitive_share_entrants#3","axis":"competitive_share_entrants","section":"coverage","direction":"-","claim":"2026 MA星等：Aetna分數下滑、UnitedHealthcare改善","source":"Fierce Healthcare: 2026 MA Star Ratings","url":"https://www.fiercehealthcare.com/regulatory/2026-ma-star-ratings-aetna-humana-see-score-decline-unitedhealthcare-improves","excerpt":null,"as_of":"2025-10-09","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"customer_second_source#0","axis":"customer_second_source","section":"coverage","direction":"-","claim":"Tyson Foods 於 2024 年 1 月改用 Rightway 取代 CVS Caremark（個別客戶流失，非最大客戶）","source":"BenefitsPRO","url":"https://benefitspro.com/2024/01/26/tyson-foods-drops-cvs-caremark-for-startup-pbm-more-shakeups-to-come","excerpt":null,"as_of":"2024-01-26","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"customer_second_source#1","axis":"customer_second_source","section":"coverage","direction":"-","claim":"Blue Shield of California 2023 年起不再以 Caremark 為主要 PBM","source":"Axios","url":"https://www.axios.com/2023/08/17/cvs-shares-tank-insurer-cuts-pbm-relationship","excerpt":null,"as_of":"2023-08-17","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"customer_second_source#2","axis":"customer_second_source","section":"coverage","direction":"+","claim":"CalPERS 五年 Medicare PBM 合約自 2026-01-01 起交給 CVS Caremark，取代 Optum Rx","source":"AIS Health","url":"https://aishealth.mmitnetwork.com/blogs/radar-on-drug-benefits/news-briefs-calpers-signs-pbm-deal-with-cvs-caremark","excerpt":null,"as_of":"2025-10-01","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"customer_concentration_credit#0","axis":"customer_concentration_credit","section":"coverage","direction":"0","claim":"聯邦政府（主要為 CMS）占 CVS 合併營收約 20%（2025/2024/2023）；CMS 的 Medicare 合約占聯邦政府營收 79%（2025）、74%、73%；除 CMS 外 Health Care Benefits 不依賴單一或少數客戶。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"Health Care Benefits segment revenues from the federal government accounted for approximately 20% of the Company’s consolidated total revenues in 2025, 2024 and 2023. Contracts with CMS for coverage of Medicare-eligible individuals in the Health Care Benefits segment accounted for approximately 79%, 74% and 73%, respectively, of the Company’s consolidated revenues from the federal government in 2025, 2024 and 2023.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"customer_concentration_credit#1","axis":"customer_concentration_credit","section":"coverage","direction":"0","claim":"Pharmacy & Consumer Wellness 無單一付款方占合併營收 10% 以上（2025/2024/2023）。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"No single Pharmacy & Consumer Wellness payor accounted for 10% or more of the Company’s consolidated total revenues in 2025, 2024 or 2023.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R"],"status":"ok"},{"id":"customer_concentration_credit#2","axis":"customer_concentration_credit","section":"coverage","direction":"0","claim":"CVS 10-Q（2026-06-30）列示長期評等 Fitch BBB（展望負面）、Moody's Baa3（穩定）、S&P BBB（2026-05 展望由負面調為穩定）；2026 年未見降評。","source":"SEC EDGAR 10-Q 2026-06-30","url":"https://www.sec.gov/Archives/edgar/data/0000064803/000006480326000098/cvs-20260630.htm","excerpt":"Company’s long-term debt was rated “BBB” by Fitch Ratings, Inc. (“Fitch”), “Baa3” by Moody’s Ratings (“Moody’s”) and “BBB” by Standard & Poor’s Financial Services LLC (“S&P”), and its commercial paper program was rated “F2” by Fitch, “P-3” by Moody’s and “A-2” by S&P. The outlook on the Company’s long-term debt is “Negative” by Fitch and “Stable” by Moody’s.","as_of":"2026-08-01","retrieved_at":"20261108","affects":["valuation","decision_inputs.bear"],"status":"ok"},{"id":"supply_demand_durability#0","axis":"supply_demand_durability","section":"coverage","direction":"0","claim":"CMS 2027 MA final rate 預估淨平均增 2.48%（預告為 0.09%）；CVS CEO 稱仍低於醫療成本趨勢，但維持 2028 年達 MA 目標利潤率的路徑","source":"Fierce Healthcare / rallies.ai 報導 CMS 2027 MA 費率","url":"https://rallies.ai/news/cvs-jumps-as-cms-boosts-2027-medicare-advantage-rates-aiding-aetna-outlook","excerpt":null,"as_of":"2026-04-06","retrieved_at":"20261108","affects":["thesis.H","thesis.R","valuation"],"status":"ok"},{"id":"supply_demand_durability#1","axis":"supply_demand_durability","section":"coverage","direction":"+","claim":"Q2 2026 Aetna MA 優於預期，歸因於削減福利、退出不賺錢市場、醫療成本管理與定價紀律；管理層稱 2027 延續同樣紀律","source":"Healthcare Dive: CVS triples net income Q2 2026, raises outlook","url":"https://www.healthcaredive.com/news/cvs-triples-net-income-q2-2026-raises-outlook/827041/","excerpt":null,"as_of":"2026-08-01","retrieved_at":"20261108","affects":["moat_trend","thesis.H"],"status":"ok"},{"id":"supply_demand_durability#2","axis":"supply_demand_durability","section":"coverage","direction":"-","claim":"WSJ 專欄認為保險業 Medicare 危機已過、容易的獲利改善也已過，現價已反映相當程度的利潤率修復","source":"WSJ Heard on the Street: The Medicare Crisis for Insurers Is Over. The Easy Gains Are Too.","url":"https://www.itiger.com/news/2644712935","excerpt":null,"as_of":"2026-07-01","retrieved_at":"20261108","affects":["valuation","decision_inputs.bear"],"status":"ok"},{"id":"regulatory_antitrust#0","axis":"regulatory_antitrust","section":"coverage","direction":"-","claim":"10-K 載明：CMS 每年稽核所有 Medicare Advantage 合約（RADV），DOJ 民事部門就風險調整診斷碼寄出 CID；風險調整機制變動可能實質影響 Medicare 給付。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"The Company also has received Civil Investigative Demands (“CIDs”) from, and provided documents and information to, the Civil Division of the DOJ in connection with investigations of the Company’s identification and/or submission of diagnosis codes related to risk adjustment payments","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"regulatory_antitrust#1","axis":"regulatory_antitrust","section":"coverage","direction":"-","claim":"10-K 載明：若公司在相關市場有實際或潛在市場力，其商業安排可能受 FTC／州／聯邦監管機關加強審查與挑戰。","source":"SEC EDGAR 10-K FY2025 Item 1 Antitrust and Unfair Competition","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"To the extent that the Company appears to have actual or potential market power in a relevant market or CVS pharmacy, CVS specialty or MinuteClinic plays a unique or expanded role in a Health Care Benefits or Health Services segment product offering, the Company’s business arrangements and uses of confidential information may be subject to heightened scrutiny","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"regulatory_antitrust#2","axis":"regulatory_antitrust","section":"coverage","direction":"-","claim":"搜尋摘要：佛州檢察長就 Caremark 是否導流至自家藥局、對關係藥局給付較優，對 CVS 發出民事調查令（CID）；尚未指控違法，CVS 表示配合但不同意其損害理論。","source":"Duane Morris, Florida Attorney General Examines Alleged Anticompetitive Pharmacy Practices by PBM, Parent Company","url":"https://blogs.duanemorris.com/stateattorneysgeneral/2026/07/23/florida-attorney-general-examines-alleged-anticompetitive-pharmacy-practices-by-pbm-parent-company/","excerpt":null,"as_of":"2026-07-23","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"regulatory_antitrust#3","axis":"regulatory_antitrust","section":"coverage","direction":"-","claim":"眾議院司法委員會 2026-01 中期報告稱 CVS 可能以 Caremark 針對獨立及數位競爭藥局而違反反托拉斯法","source":"fintool, cvs antitrust house report","url":"https://fintool.com/news/cvs-antitrust-house-report","excerpt":null,"as_of":"2026-01-31","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"reg_tariff_export#0","axis":"reg_tariff_export","section":"coverage","direction":"-","claim":"10-K風險因素：CVS藥局銷售的品牌與學名藥及其他商品多數全部或大部分在美國境外製造，由他人進口後賣給CVS；關稅或貿易政策重大變動可能顯著推高成本、限制供應商取得，並對業務產生重大不利影響；現任政府已課徵且可能進一步加徵關稅。","source":"SEC EDGAR 10-K FY2025 Item 1A","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"Much of the branded and generic drug product that we sell in our pharmacies, and much of the other merchandise we sell, is manufactured in whole or in substantial part outside of the U.S. In most cases, the products or merchandise are imported by others and sold to us.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"reg_tariff_export#1","axis":"reg_tariff_export","section":"coverage","direction":"-","claim":"10-K MD&A將新關稅或關稅變動列為可能增加成本、造成供應鏈中斷並影響消費需求、為客戶創造節省的能力或公司財務結果的因素。","source":"SEC EDGAR 10-K FY2025 Item 7 MD&A","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"Changes in the economic environment, including inflation, the implementation of new tariffs or changes in tariffs, including the impact of tariffs on trade relations between the U.S. and foreign countries, and labor and other market dynamics could create exposure for increased costs and supply chain disruptions","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R"],"status":"ok"},{"id":"reg_tariff_export#2","axis":"reg_tariff_export","section":"coverage","direction":"0","claim":"10-K Item 1：海外業務受OFAC制裁及貿易法規約束；摘錄未見出口管制或實體清單事件。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"The Company also is subject to regulation by the Office of Foreign Assets Control of the U.S. Department of Treasury (“OFAC”).","as_of":"2026-02-10","retrieved_at":"20261108","affects":["thesis.R"],"status":"ok"},{"id":"reg_tariff_export#3","axis":"reg_tariff_export","section":"coverage","direction":"-","claim":"2026-04-02公告的Section 232藥品關稅：專利藥及原料藥預設100%，歐盟/日本/韓國/瑞士15%，學名藥暫時排除、一年後重審；搜尋結果未點名CVS。","source":"Polsinelli, Trump Administration Expands Section 232 Tariffs to Patented Pharmaceuticals and APIs（經搜尋摘要）","url":"https://www.polsinelli.com/publications/trump-administration-expands-section-232-tariffs-to-patented-pharmaceuticals-and-apis","excerpt":null,"as_of":"2026-04-02","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"geo_supply_chain#0","axis":"geo_supply_chain","section":"coverage","direction":"-","claim":"CVS 年報揭露：郵購與特殊藥局大量藥品來自少數供應商，部分情況依賴單一來源。","source":"CVS Health Form ARS FY2025","url":"https://www.sec.gov/Archives/edgar/data/64803/000130817926000203/cvs014969-ars.pdf","excerpt":"We acquire a substantial amount of our mail order and specialty pharmacies' prescription drug supply from a limited number of suppliers. In some cases, we depend upon a single source of supply.","as_of":"2026-03-01","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"geo_supply_chain#1","axis":"geo_supply_chain","section":"coverage","direction":"-","claim":"CVS 年報揭露：藥局銷售的品牌與學名藥及其他商品，大部分全部或實質部分在美國境外製造；關稅或貿易變動可能推高成本。","source":"CVS Health Form ARS FY2025","url":"https://www.sec.gov/Archives/edgar/data/64803/000130817926000203/cvs014969-ars.pdf","excerpt":"Much of the branded and generic drug product that we sell in our pharmacies, and much of the other merchandise we sell, is manufactured in whole or in substantial part outside of the U.S.","as_of":"2026-03-01","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"geo_supply_chain#2","axis":"geo_supply_chain","section":"coverage","direction":"-","claim":"CVS 年報揭露：許多藥局產品的成分易受供應短缺影響。","source":"CVS Health Form ARS FY2025","url":"https://www.sec.gov/Archives/edgar/data/64803/000130817926000203/cvs014969-ars.pdf","excerpt":"Many products distributed by our pharmacies are manufactured with ingredients that are susceptible to supply shortages.","as_of":"2026-03-01","retrieved_at":"20261108","affects":["thesis.R"],"status":"ok"},{"id":"end_markets#0","axis":"end_markets","section":"coverage","direction":"+","claim":"CVS Q3 2026 總營收 1084 億美元，年增 5.4%；EPS 成長主因 Health Care Benefits 營業利益改善（保費回復計畫）","source":"CVS Health Q3 2026 earnings press release","url":"https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html","excerpt":"Third quarter total revenues increased to $108.4 billion, up 5.4% year-over-year.","as_of":"2026-11-04","retrieved_at":"20261108","affects":["thesis.H","valuation"],"status":"ok"},{"id":"end_markets#1","axis":"end_markets","section":"coverage","direction":"+","claim":"CMS 2027 Medicare Advantage 最終費率平均淨增 2.48%（初稿僅 0.09%）；Aetna 2027 MA 計畫將更多採窄網路","source":"搜尋摘要（聚合/Reuters 轉述）：Medicare Advantage 2027 coverage","url":"https://www.webull.com/news/15691409060070400","excerpt":null,"as_of":"2026-10-03","retrieved_at":"20261108","affects":["thesis.H","valuation"],"status":"ok"},{"id":"end_markets#2","axis":"end_markets","section":"coverage","direction":"0","claim":"CVS 零售藥局處方市佔逾 29%；Q2 2026 處方量年增 4.3%，Rite Aid 檔案收購紅利預期將趨緩","source":"Motley Fool Q1 2026 earnings call transcript / Hudson Labs Q3 preview","url":"https://www.hudson-labs.com/research/cvs-q3-2026-earnings-preview-cvs-revenue-eps-guidance","excerpt":null,"as_of":"2026-10-20","retrieved_at":"20261108","affects":["moat_trend","thesis.R"],"status":"ok"},{"id":"end_markets#3","axis":"end_markets","section":"coverage","direction":"-","claim":"Drug Channels：2025 年 Caremark 理賠量連續第二年下降，Express Scripts 持續領先；Caremark 2023 年高峰 23 億件","source":"Drug Channels 'The Top Pharmacy Benefit Managers' 2026","url":"https://www.drugchannels.net/2026/06/the-top-pharmacy-benefit-managers-of.html","excerpt":null,"as_of":"2026-06-09","retrieved_at":"20261108","affects":["moat_trend","decision_inputs.bear"],"status":"ok"},{"id":"end_markets#4","axis":"end_markets","section":"coverage","direction":"-","claim":"Q3 2026 Pharmacy & Consumer Wellness 營收下滑，歸因法規降價、學名藥上市與給付壓力；商業保費下降 16.9%（Stocktwits 轉述）","source":"Stocktwits/Zacks Q3 2026 摘要","url":"https://stocktwits.com/symbol/CVS/earnings","excerpt":null,"as_of":"2026-11-04","retrieved_at":"20261108","affects":["thesis.R","decision_inputs.bear"],"status":"ok"},{"id":"end_markets#5","axis":"end_markets","section":"coverage","direction":"0","claim":"Q3 2026 各段營收（Health Care Benefits/Health Services/Pharmacy & Consumer Wellness）","source":"CVS 8-K Ex.99.1 Q3 2026","url":"https://www.sec.gov/Archives/edgar/data/0000064803/000006480326000107/cvs_ex99x1q3-26.htm","excerpt":"In millions Health Care Benefits Health Services Pharmacy & Consumer Wellness Corporate/ Other Consolidated Totals Operating income (loss) (GAAP measure) $ 653 $ 1,980 $ 1,573 $ (640) $ 3,566","as_of":"2026-11-04","retrieved_at":"20261108","affects":["thesis.H"],"status":"ok"},{"id":"substitute_technology#0","axis":"substitute_technology","section":"coverage","direction":"-","claim":"CVS 10-K 稱破壞式創新（現有或新競爭者）已改變且預期持續改變競爭格局，且購買決策越來越由消費者透過公開／私有交易所主導，需發展新能力。","source":"SEC EDGAR 10-K FY2025 Item 1A","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"Disruptive innovation by existing or new competitors has altered, and is expected to continue to alter, the competitive landscape in the future and require us to accurately identify and assess such alterations and make timely and effective changes to our strategies and business model to compete effectively.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["moat_trend","decision_inputs.bear"],"status":"ok"},{"id":"substitute_technology#1","axis":"substitute_technology","section":"coverage","direction":"-","claim":"10-K 列出新興競爭者：新創健保、醫療體系自有保險、非傳統通路（零售）等。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"Emerging competitors include start up health care benefits plans, provider-owned health 6 plans, new joint ventures (including not-for-profit joint ventures among firms from multiple industries), financial services firms that are distributing competing products on their proprietary Private Exchanges","as_of":"2026-02-10","retrieved_at":"20261108","affects":["moat_trend","thesis.R"],"status":"ok"},{"id":"substitute_technology#2","axis":"substitute_technology","section":"coverage","direction":"-","claim":"Blue Shield of California 將 PBM 業務由 CVS Caremark 拆給 Amazon Pharmacy、Cost Plus Drugs 等多家（2023 宣布，2025 全面上線），為 PBM 替代模式的實例；非 2026 新聞。","source":"CNBC: CVS stock plunges after Blue Shield of California drops retailer's pharmacy services","url":"https://www.cnbc.com/2023/08/17/cvs-stock-blue-shield-of-california-drops-pbm-services.html","excerpt":null,"as_of":"2023-08-17","retrieved_at":"20261108","affects":["moat_trend","decision_inputs.bear"],"status":"ok"},{"id":"channel_business_model_shift#0","axis":"channel_business_model_shift","section":"coverage","direction":"0","claim":"FY2025 10-K：CVS 提供訂閱制會員方案 ExtraCare Plus；2025 年關閉 221 家零售門市；10-K 並指出產業朝消費者導向的零售市場（私有／公共交易所）演進，增加新進者與非傳統通路（如零售業者）的競爭風險。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"The Company also offers a subscription-based membership program, ExtraCare PlusTM, under which members are entitled to a suite of benefits delivered over the course of the subscription period","as_of":"2026-02-10","retrieved_at":"20261108","affects":["moat_trend","thesis.R"],"status":"ok"},{"id":"channel_business_model_shift#1","axis":"channel_business_model_shift","section":"coverage","direction":"-","claim":"10-K：2025 年全年關閉 221 家零售門市（企業重組計畫）。","source":"SEC EDGAR 10-K FY2025 Item 1","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"During the year ended December 31, 2025, the Company closed 221 retail stores in connection with this action.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"channel_business_model_shift#2","axis":"channel_business_model_shift","section":"coverage","direction":"-","claim":"Aetna 宣布 2026 年退出 ACA 個人交易所市場，約 100 萬會員需換保。","source":"Healthcare Dive","url":"https://www.healthcaredive.com/news/cvs-aetna-exit-aca-novo-nordisk-wegovy-deal/746833/","excerpt":"“We are disappointed by the continued underperformance from our individual exchange products and have recently determined there is not a near- or long-term pathway for Aetna to materially improve its position,” CVS CEO David Joyner told investors on a Thursday morning call.","as_of":"2025-05-01","retrieved_at":"20261108","affects":["moat_trend","thesis.R"],"status":"ok"},{"id":"channel_business_model_shift#3","axis":"channel_business_model_shift","section":"coverage","direction":"0","claim":"CVS 預期 2026 年新開店數多於關店，聚焦較小型健康導向門市。","source":"KFF Health News","url":"https://kffhealthnews.org/MjE3NjI3NQ","excerpt":null,"as_of":"2026-03-01","retrieved_at":"20261108","affects":["moat_trend"],"status":"ok"},{"id":"capital_markets_pricing#0","axis":"capital_markets_pricing","section":"coverage","direction":"+","claim":"Q3 2026（2026-11-04 公布）調高 FY26 調整後 EPS 指引至至少 $8.20（前為 $7.90–$8.10）；Yonhap 稱高於市場共識 $8.04，盤前股價約跌 1.6%，焦點在零售藥局與 PBM 分拆（目標 2028 上半年完成）","source":"CVS Health 新聞稿／Yonhap 引述（經搜尋摘要）","url":"https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html","excerpt":null,"as_of":"2026-11-04","retrieved_at":"20261108","affects":["valuation","triggers"],"status":"ok"},{"id":"capital_markets_pricing#1","axis":"capital_markets_pricing","section":"coverage","direction":"0","claim":"MarketBeat：截至 2026-08-21 目標價均值 $107.17（24 位分析師），區間 $90–$126，共識評等 Moderate Buy；Tickflow 2026-08-01 均值 $103.64；StockAnalysis（S&P Global，28 位）均值 $105、區間 $79–$140（日期不明）。此為 Q3 公布前的分布","source":"MarketBeat forecast / Tickflow / StockAnalysis（搜尋摘要）","url":"https://www.marketbeat.com/stocks/NASDAQ/CVS/forecast/","excerpt":null,"as_of":"2026-08-21","retrieved_at":"20261108","affects":["valuation"],"status":"ok"},{"id":"capital_markets_pricing#2","axis":"capital_markets_pricing","section":"coverage","direction":"+","claim":"Q3 2026 財報新聞稿：調整後 EPS 指引至少 $8.20，營運現金流至少 $15.5B","source":"SEC 8-K Ex99.1 Q3-26","url":"https://www.sec.gov/Archives/edgar/data/0000064803/000006480326000107/cvs_ex99x1q3-26.htm","excerpt":"◦Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10 ◦Cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion","as_of":"2026-11-04","retrieved_at":"20261108","affects":["valuation"],"status":"ok"},{"id":"major_events#0","axis":"major_events","section":"coverage","direction":"-","claim":"10-K FY2025 揭露：2024 年 7 月起兩件證券集體訴訟（已合併於 SDNY）及多件衍生訴訟，指控涉及健康福利部門獲利的遺漏與不實陳述；2025 年 5 月被告提出駁回動議。","source":"SEC EDGAR 10-K FY2025 Item 8","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"Beginning in July 2024, two purported class action complaints, as well as multiple derivative complaints, were filed by putative plaintiffs against the Company and certain current and former officers and directors.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["decision_inputs.bear","thesis.R"],"status":"ok"},{"id":"major_events#1","axis":"major_events","section":"coverage","direction":"-","claim":"10-K FY2025 揭露：PBM 業務面臨 FTC、州檢察長等多件訴訟與 DOJ/HHS/FTC 調查，並涉及回扣定價的集體訴訟（多數移至 NJ 聯邦地院 MDL）。","source":"SEC EDGAR 10-K FY2025 Item 8","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"The Company is facing multiple lawsuits, including by the FTC, state Attorneys General, governmental subdivisions, private parties and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["decision_inputs.bear","thesis.R"],"status":"ok"},{"id":"major_events#2","axis":"major_events","section":"coverage","direction":"0","claim":"近12個月 8-K 共 10 份，含重大項目者僅 1 份（2025-11-20 Item 8.01，任命 Joyner 兼任董事長），無 2.01/1.01/4.02 類事件。","source":"SEC EDGAR 8-K 申報清單（程式統計）","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000064803&type=8-K","excerpt":"【程式統計】SEC EDGAR 申報清單，2025-11-08 至 2026-11-08 共 10 份 8-K；其中含重大項目（1.01／1.02／1.03／2.01／2.05／2.06／3.01／4.02／5.01／8.01 等）者 1 份。","as_of":"2026-11-08","retrieved_at":"20261108","affects":["triggers"],"status":"ok"},{"id":"major_events#3","axis":"major_events","section":"coverage","direction":"-","claim":"2026 年 7 月 CPSC 公布 Diamond Wipes 代工的 CVS Health 自有品牌含利多卡因痔瘡濕巾召回（包裝非防兒童開啟）。","source":"CPSC Recalls 2026","url":"https://www.cpsc.gov/Recalls/2026/Diamond-Wipes-International-Recalls-CVS-Health-Medicated-Hemorrhoidal-Wipes-Due-to-Risk-of-Serious-Injury-or-Death-from-Child-Poisoning-Violate-Mandatory-Standard-for-Child-Resistant-Packaging","excerpt":"Diamond Wipes International Recalls CVS Health Medicated Hemorrhoidal Wipes Due to Risk of Serious Injury or Death from Child Poisoning Violate Mandatory Standard for Child Resistant Packaging","as_of":"2026-07-02","retrieved_at":"20261108","affects":["decision_inputs.bear"],"status":"ok"},{"id":"major_events#4","axis":"major_events","section":"coverage","direction":"-","claim":"2026-08-27 SDNY 法官部分駁回被告駁回動議，證券集體訴訟（Nixon v. CVS Health）進入 discovery。","source":"BFA Law 案件更新","url":"https://www.bfalaw.com/news/case-updates/2026-08-28-bfa-defeats-motion-to-dismiss-in-cvs-securities-litigation","excerpt":"BFA Defeats Motion to Dismiss in CVS Securities Litigation August 28, 2026 On August 27, 2026, Judge Margaret M. Garnett of the Southern District of New York partially denied Defendants’ motion to dismiss the securities fraud class action Nixon v.","as_of":"2026-08-28","retrieved_at":"20261108","affects":["decision_inputs.bear","thesis.R"],"status":"ok"},{"id":"major_events#5","axis":"major_events","section":"coverage","direction":"-","claim":"2026年4月 KC Pharmaceuticals 代工之含 CVS 自有品牌眼藥水逾 300 萬瓶 FDA Class II 召回（微生物污染疑慮）。","source":"6abc / Good Morning America","url":"https://6abc.com/post/3-million-bottles-eye-drops-sold-cvs-kroger-more-voluntarily-recalled/18835267/","excerpt":"The recalled eye drops were produced by KC Pharmaceuticals Inc., a private label maker, and were sold under multiple brand names, including Best Choice, CVS, Discount Drug Mart, Gericare, Kroger and Walgreens. The drops were initially recalled on March 3, according to the FDA. On March 31, the FDA assigned the recall a Class II designation, defined by the agency as a","as_of":"2026-04-03","retrieved_at":"20261108","affects":["decision_inputs.bear"],"status":"ok"},{"id":"ma_merger#0","axis":"ma_merger","section":"events","direction":"0","claim":"近12個月 8-K 清單無 Item 1.01/2.01 等併購類項目；僅 1 份重大項目為董事長任命（8.01）。搜尋未見 2026 年新併購。","source":"SEC EDGAR 8-K 申報清單（程式統計）","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000064803&type=8-K","excerpt":"【程式統計】SEC EDGAR 申報清單，2025-11-08 至 2026-11-08 共 10 份 8-K；其中含重大項目（1.01／1.02／1.03／2.01／2.05／2.06／3.01／4.02／5.01／8.01 等）者 1 份。","as_of":"2026-11-08","retrieved_at":"20261108","affects":["triggers"],"status":"ok"},{"id":"lawsuit_class_action#0","axis":"lawsuit_class_action","section":"events","direction":"-","claim":"證券集體訴訟（SDNY，Louisiana Sheriffs'）與衍生訴訟進行中，被告 2025-05 提出駁回動議。","source":"SEC EDGAR 10-K FY2025 Item 8","url":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm","excerpt":"In May 2025, the defendants filed a motion to dismiss the amended consolidated class action complaint captioned as Louisiana Sheriffs’ Pension and Relief Fund, et al. v. CVS Health Corp., et al.","as_of":"2026-02-10","retrieved_at":"20261108","affects":["decision_inputs.bear","thesis.R"],"status":"ok"},{"id":"clinical_fda#none","axis":"clinical_fda","section":"events","direction":null,"claim":null,"status":"none","source":null,"as_of":null},{"id":"product_recall_warning#0","axis":"product_recall_warning","section":"events","direction":"-","claim":"2026-07-02 CPSC 公布 CVS Health 自有品牌痔瘡濕巾召回（代工 Diamond Wipes，包裝非防兒童開啟）。","source":"CPSC Recalls 2026","url":"https://www.cpsc.gov/Recalls/2026/Diamond-Wipes-International-Recalls-CVS-Health-Medicated-Hemorrhoidal-Wipes-Due-to-Risk-of-Serious-Injury-or-Death-from-Child-Poisoning-Violate-Mandatory-Standard-for-Child-Resistant-Packaging","excerpt":"Diamond Wipes International Recalls CVS Health Medicated Hemorrhoidal Wipes Due to Risk of Serious Injury or Death from Child Poisoning Violate Mandatory Standard for Child Resistant Packaging","as_of":"2026-07-02","retrieved_at":"20261108","affects":["decision_inputs.bear"],"status":"ok"},{"id":"sec_investigation_restatement#0","axis":"sec_investigation_restatement","section":"events","direction":"0","claim":"近12個月 8-K 無 Item 4.02（財報不可信賴）；搜尋未見 2026 年 SEC 調查或重編。10-K 所列調查為 DOJ/HHS/FTC/州檢察長（PBM 業務），非 SEC。","source":"SEC EDGAR 8-K 申報清單（程式統計）","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000064803&type=8-K","excerpt":"【程式統計】SEC EDGAR 申報清單，2025-11-08 至 2026-11-08 共 10 份 8-K；其中含重大項目（1.01／1.02／1.03／2.01／2.05／2.06／3.01／4.02／5.01／8.01 等）者 1 份。","as_of":"2026-11-08","retrieved_at":"20261108","affects":["triggers"],"status":"ok"}],"gaps":[{"topic":"同業對照缺度量：rd_intensity_pct","question":"q2_moat","why":"evidence.numbers.peer_financials 該欄整欄為 null（常見於未單獨揭露研發的業者），事實表 agent 若能從財報補就補，補不到即為缺口，判斷者不得自行估。","tried":["evidence.numbers.peer_financials"]},{"topic":"法說問答未正面回答項","question":"q6_how_wrong","why":"digest.qa_flags 有 4 條管理層迴避紀錄，內容須由事實表 agent 逐條落成事實或缺口","tried":["digest.qa_flags"]}],"peer_comparison":{"metrics":[{"key":"gross_margin_pct","label":"毛利率","unit":"%"},{"key":"operating_margin_pct","label":"營業利益率","unit":"%"},{"key":"fcf_margin_pct","label":"FCF 利潤率","unit":"%"}],"rows":[{"name":"CVS","period":"TTM ending 2026-09-30（4季加總）","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","values":{"gross_margin_pct":14.23,"operating_margin_pct":3.58,"fcf_margin_pct":3.7,"rd_intensity_pct":null},"source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CVS","as_of":"TTM ending 2026-09-30（4季加總）"},"is_subject":true,"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"name":"CI","period":"TTM ending 2026-09-30（4季加總）","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","values":{"gross_margin_pct":8.79,"operating_margin_pct":3.1,"fcf_margin_pct":2.82,"rd_intensity_pct":null},"source":{"type":"evidence_numbers","ref":"numbers.peer_financials.CI","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"name":"UNH","period":"TTM ending 2026-09-30（4季加總）","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","values":{"gross_margin_pct":19.84,"operating_margin_pct":5.32,"fcf_margin_pct":5.08,"rd_intensity_pct":null},"source":{"type":"evidence_numbers","ref":"numbers.peer_financials.UNH","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"name":"ELV","period":"TTM ending 2026-09-30（4季加總）","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","values":{"gross_margin_pct":null,"operating_margin_pct":null,"fcf_margin_pct":3.23,"rd_intensity_pct":null},"source":{"type":"evidence_numbers","ref":"numbers.peer_financials.ELV","as_of":"TTM ending 2026-09-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"},{"name":"HUM","period":"TTM ending 2026-06-30（4季加總）","basis":"yfinance quarterly_income_stmt／quarterly_cashflow（TTM sum，最近可得季數）","values":{"gross_margin_pct":null,"operating_margin_pct":null,"fcf_margin_pct":1.34,"rd_intensity_pct":null},"source":{"type":"evidence_numbers","ref":"numbers.peer_financials.HUM","as_of":"TTM ending 2026-06-30（4季加總）"},"note":"Research And Development 該公司未單獨揭露（常見於硬體/非軟體業者）"}],"subject":"CVS"},"financial_history":{"ticker":"CVS","currency":"USD","method":"年度財報（yfinance annual income_stmt／cashflow，非 TTM），最近 4 個會計年度、舊到新排列；FCF＝Operating Cash Flow + Capital Expenditure（yfinance 的 Capital Expenditure 本身已為負值，相加即等於「營業現金流−資本支出」）。","source":"yfinance income_stmt／cashflow（annual）","note":null,"years":[{"fiscal_year_end":"2022-12-31","revenue":322467000000.0,"revenue_yoy_pct":null,"gross_margin_pct":16.9,"operating_margin_pct":5.05,"net_income":4311000000.0,"diluted_eps":3.26,"free_cash_flow":13450000000.0,"fcf_margin_pct":4.17,"source":{"type":"evidence_numbers","ref":"numbers.financial_history.years[0]","as_of":"2022-12-31","citation":"年度財報（yfinance annual income_stmt／cashflow，非 TTM），最近 4 個會計年度、舊到新排列；FCF＝Operating Cash Flow + Capital Expenditure（yfinance 的 Capital Expenditure 本身已為負值，相加即等於「營業現金流−資本支出」）。"}},{"fiscal_year_end":"2023-12-31","revenue":357776000000.0,"revenue_yoy_pct":10.95,"gross_margin_pct":15.21,"operating_margin_pct":4.08,"net_income":8344000000.0,"diluted_eps":6.47,"free_cash_flow":10395000000.0,"fcf_margin_pct":2.91,"source":{"type":"evidence_numbers","ref":"numbers.financial_history.years[1]","as_of":"2023-12-31","citation":"年度財報（yfinance annual income_stmt／cashflow，非 TTM），最近 4 個會計年度、舊到新排列；FCF＝Operating Cash Flow + Capital Expenditure（yfinance 的 Capital Expenditure 本身已為負值，相加即等於「營業現金流−資本支出」）。"}},{"fiscal_year_end":"2024-12-31","revenue":372809000000.0,"revenue_yoy_pct":4.2,"gross_margin_pct":13.79,"operating_margin_pct":2.6,"net_income":4614000000.0,"diluted_eps":3.66,"free_cash_flow":6326000000.0,"fcf_margin_pct":1.7,"source":{"type":"evidence_numbers","ref":"numbers.financial_history.years[2]","as_of":"2024-12-31","citation":"年度財報（yfinance annual income_stmt／cashflow，非 TTM），最近 4 個會計年度、舊到新排列；FCF＝Operating Cash Flow + Capital Expenditure（yfinance 的 Capital Expenditure 本身已為負值，相加即等於「營業現金流−資本支出」）。"}},{"fiscal_year_end":"2025-12-31","revenue":402067000000.0,"revenue_yoy_pct":7.85,"gross_margin_pct":13.77,"operating_margin_pct":2.58,"net_income":1768000000.0,"diluted_eps":1.39,"free_cash_flow":7807000000.0,"fcf_margin_pct":1.94,"source":{"type":"evidence_numbers","ref":"numbers.financial_history.years[3]","as_of":"2025-12-31","citation":"年度財報（yfinance annual income_stmt／cashflow，非 TTM），最近 4 個會計年度、舊到新排列；FCF＝Operating Cash Flow + Capital Expenditure（yfinance 的 Capital Expenditure 本身已為負值，相加即等於「營業現金流−資本支出」）。"}}]}}
```

---

## ④ 最新一季逐字稿全文

（來源：/Users/ivanchang/Library/CloudStorage/GoogleDrive-keigoks@gmail.com/我的雲端硬碟/007美股/CVS/CVS_Q3_2026_Earnings_Call_20261104.md）

# Q3 2026 Earnings Call
**CVS Health Corporation** | Earnings Calls | 2026-11-04

**Operator** (Operator):
Hello, and welcome to CVS Health's Third Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time.
I would now like to pass the call to Larry McGrath. Larry, please proceed.

**Larry McGrath** (Executives):
Good morning, and welcome to the CVS Health Third Quarter 2026 Earnings and Business Update Call and Webcast. I'm Larry McGrath, Executive Vice President of Capital Markets at CVS Health. I'm joined this morning by David Joyner, Chairman and Chief Executive Officer; and Brian Newman, Chief Financial Officer.
Following our prepared remarks, we'll host a question-and-answer session that will include additional members of the leadership team. Our press releases and slide presentations have been posted to our website, along with our Form 10-Q filed this morning with the SEC. Today's call is also being broadcast on our website.
During this call, we'll make certain forward-looking statements. Our forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from currently projected results. We strongly encourage you to review the reports we file with the SEC regarding these risks and uncertainties. In particular, those that are described in the cautionary statement concerning forward-looking statements and risk factors in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q filed this morning, and our recent filings on Form 8-K, including this morning's earnings press release.
During this call, we'll use certain non-GAAP measures when talking about the company's financial performance and financial condition, and you can find a reconciliation of these non-GAAP measures in this morning's press release and in the reconciliation document posted to the Investor Relations portion of our website.
With that, I'd like to turn the call over to David. David?

**J. Joyner** (Executives):
Thank you, Larry, and good morning, everyone. Our organization has a long and distinguished history. And in my 40 years at this company, there has been one constant: we act, we evolve, and we proactively shape the future of health care. Today, we announced our intention to separate into 2 independent, publicly traded companies. This decision marks the next important chapter in the evolution of CVS Health.
We are creating 2 distinct leaders in health care. The first will be a health care solutions company that brings together medical, pharmacy, specialty, and care delivery capabilities integrated where it matters. In the interim period, we are referring to this business as CVS Health. The second company will be a leading national retail pharmacy and community health care company. This business will be named CVS Pharmacy. Both companies will be led by experienced leadership teams, have a clear right to win in their respective markets, and we expect will be supported by solid investment-grade balance sheets, enabling each company to pursue disciplined and tailored capital allocation. We take this action from a position of strength, which you can see in the consistent progress we've made since 2024, as well as in the third quarter results and the updated guidance we announced this morning.
This quarter, we generated adjusted operating income of $4.2 billion and adjusted earnings per share of $2.09. Building on our continued strong performance so far this year, we are raising our full year 2026 adjusted earnings per share guidance to at least $8.20, an increase from our prior range of $7.90 to $8.10. We are also updating our full year expectation for cash flow from operations to at least $15.5 billion. With this latest update, our 2026 adjusted EPS guidance is now more than $1 above our initial expectations for 2026. And our cash flow from operations outlook has increased by more than $5.5 billion for the year. This progress clearly reflects our growing momentum.
I'll now ask Brian to provide more details on results this quarter, our updated full year 2026 guidance, and perspective on the factors shaping our 2027 expectations. I will then come back to provide more details on our announcement. Brian?

**Brian Newman** (Executives):
Thank you, David, and good morning. I will cover 4 key topics in my remarks this morning. First, an update on our third quarter results. Second, I'll discuss cash flow, the balance sheet, and capital deployment. After that, I will provide an updated financial outlook for 2026. And finally, I will share some headwinds and tailwinds as we look ahead to 2027.
Our third quarter results demonstrate the discipline with which we continue to manage the enterprise. We once again delivered on our commitments and raised our full year outlook for revenue, adjusted EPS, and cash flow from operations. Our execution has significantly strengthened our balance sheet, allowing us to achieve target leverage ahead of schedule and will enable us to resume our share repurchase program in the fourth quarter.
Let me start by highlighting some of our enterprise results in the quarter. We generated over $108 billion of revenue and delivered nearly $4.2 billion of adjusted operating income, once again reflecting earnings growth across all of our operating segments. We delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. And finally, in the quarter, we generated cash flow from operations of approximately $4.7 billion, bringing our year-to-date cash flow from operations to $15.3 billion.
Turning now to each of our segments. In Health Care Benefits, we continue to make strong progress in our return to target margins. In the quarter, we delivered adjusted operating income of approximately $900 million, an increase of nearly $600 million from the prior year quarter. Our medical benefit ratio was 91.3%, an improvement of approximately 150 basis points from the prior year.
These results were primarily driven by improved underlying performance in our Medicare business.
Across our businesses, we continue to successfully navigate elevated trends that remain above historical levels throughout the industry, but were broadly in line with our expectations. Performance in our Medicare book modestly exceeded our expectations, driven by pockets of favorability as a result of strong medical cost management and disciplined pricing. We remain confident in the adequacy of our reserves.
In our Health Services segment, we continue to execute against our objectives. During the quarter, we delivered adjusted operating income of $2.1 billion, an increase of nearly 3% from the prior year quarter, primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements. Results in our Pharmacy Services business were in line with our expectations during the quarter, including performance in both our 340B business and rebate guarantees. Health Care Delivery also performed as expected, as we continue to drive improvement in the business.
Our Pharmacy & Consumer Wellness segment delivered another strong quarter. We generated adjusted operating income of over $1.6 billion, an increase of over 10% from the prior year, primarily driven by core pharmacy strength, including a nearly 4% increase in same-store prescription volumes, partially offset by continued business investments and the impact of consumer dynamics.
Turning now to cash flow and the balance sheet. Year-to-date, we have generated cash flow from operations of $15.3 billion, reflecting strong earnings as well as the impact of improvements in working capital. So far in 2026, we have returned nearly $2.6 billion to our shareholders through our shareholder dividend. We ended the quarter with nearly $6 billion of cash at the parent and unrestricted subsidiaries. As I mentioned earlier, we have made significant progress strengthening our balance sheet and have achieved our leverage goal ahead of schedule. This improved position, combined with our strong cash flow, will enable us to resume our share repurchase program in the fourth quarter.
Shifting now to our guidance for 2026. We are increasing our full year 2026 guidance for adjusted EPS to at least $8.20, an increase of $0.20 from the midpoint of our previous outlook. We now also expect our full year total revenues to be at least $420 billion. In our Health Care Benefits segment, we now expect full year adjusted operating income to be at least $5.4 billion, an increase of $200 million relative to the midpoint of our prior outlook. We now expect our full year MBR to be in the lower half of our previously discussed range of 89.75%, plus or minus 25 basis points. This outlook continues to maintain a respectful and prudent view of medical cost trends.
In our Pharmacy & Consumer Wellness segment, we now expect full year adjusted operating income of at least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% growth from the prior year. This reflects our strong performance in the quarter and our updated expectations for the remainder of the year. We are also reiterating our full year adjusted operating income outlook for our Health Services segment. In aggregate, we now expect full year enterprise adjusted operating income to be at least $17.05 billion.
We are also increasing our outlook for full year cash flow from operations to at least $15.5 billion, reflecting our updated earnings outlook as well as the impact of working capital improvements and the timing of certain payments. Cash generation has long been a strength of this enterprise, and we continue to build on that strength as we deliver on our embedded earnings and unlock further working capital efficiencies. You can find additional details on the components of our updated 2026 guidance on our Investor Relations website.
Turning now to 2027. Consistent with past practice, we expect to provide formal 2027 guidance on our fourth quarter earnings call early next year. Today, I will share an update on some of the key headwinds and tailwinds we are considering for 2027. Starting first with our Health Care Benefits business, we expect another year of meaningful margin improvement as Aetna makes strong progress on its path back to target margins. Once again, this improvement will be largely driven by the deliberate actions we took in our Medicare Advantage business, along with continued disciplined underwriting and pricing across our businesses in response to the elevated trend environment we expect will persist in 2027.
In our Health Services segment, we expect to generate adjusted operating income of at least $7 billion. This includes our previously discussed expectations for a year-on-year decline in our 340B business as well as headwinds from the impact of a less robust selling season and health plan client membership attrition. We also expect tailwinds from continued strength in specialty and another year of improvement in our Health Care Delivery business. We continue to expect our 340B business to largely stabilize by the end of next year, and we have confidence as we enter the 2028 PBM selling season. We are confident 2027 will reflect trough earnings for the segment, and we expect to return to growth from there.
In our Pharmacy & Consumer Wellness business, we expect adjusted operating income to grow low single digits off our current 2026 guidance of at least $6.5 billion, driven by continued pharmacy strength. This marks the third consecutive year of growth in earnings for this segment. Our updated outlook reflects the progress we've made differentiating our business and solidifying our position as the best-run national pharmacy while maintaining a prudent view of consumer dynamics.
Pulling it all together and reflecting the strong performance we saw in the third quarter, we now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline. Our strong results demonstrate the progress we're making across the enterprise. We've strengthened our financial position, created greater capacity for capital deployment, and built increased confidence in the long-term expectations we outlined at Investor Day.
We now believe we will be in the high end of our mid-teens adjusted EPS CAGR through 2028. Importantly, these expectations remain grounded in the same guidance philosophy of establishing credible targets, delivering with disciplined execution and highlighting opportunities for outperformance. We will continue delivering on our say-do ratio, and that discipline will remain as we progress towards separation.
With that, I'll now turn the call back over to David. David?

**J. Joyner** (Executives):
Thank you, Brian. As Brian highlighted, we are executing against our strategy, and our businesses continue to deliver durable results. Today, we announced that we are building on that momentum. CVS Health is taking an important step in its evolution to create 2 independent, publicly traded companies. Each of the 2 companies will remain a leader in their respective markets, powered by the right assets, the right focus and the ability to adapt and move faster.
We can take this strategic action today because of our tremendous progress since 2024. We rebuilt our leadership team and instilled a clear culture of accountability, excellence and execution across the organization. We significantly improved our financial performance, strengthened our balance sheet and reached our target leverage ratio ahead of schedule, creating capacity for disciplined capital deployment. We expanded our technology capabilities across our enterprise, thoughtfully embedding AI throughout our businesses and creating a differentiated foundation to simplify and improve the health care experience.
As we've consistently demonstrated, we are making great strides delivering against our goals while remaining focused on improving the health and care of the 185 million people we serve. As we have advanced our strategy, the environment around us is constantly changing. We will be better positioned to address this changing environment as 2 strong independent health care leaders. Following a thoughtful and deliberate strategic review by the Board and senior management, we have a structure and plan that are built to win and represent the best path to create value over the long term.
As we announced, CVS Health will retain Aetna, Caremark and Pharmacy Services, specialty pharmacy, Oak Street and Signify Health. This enables us to maintain and expand integration where it matters, combining the tools necessary to improve affordability within medical and pharmacy benefits and deliver care to high-acuity populations, including in Medicare and specialty pharmacy. CVS Pharmacy will be the leading national retail pharmacy and community health care company. It will include our retail pharmacy stores, mail order, MinuteClinic and Health100, our AI-native integrated health care engagement platform for consumers.
The rationale for the separation is simple with 4 clear benefits. First, focus. Each company will have an experienced, dedicated leadership team that can concentrate on the areas where it has the greatest opportunity to create value. The same mission, sharper focus. Second, capital allocation. Each company is expected to have a solid investment-grade capital structure and strong free cash flow. This will enable tailored capital allocation more closely aligned with each company's strategy and growth opportunities. What will not change is the discipline that each company demonstrates in the deployment of capital.
Third is agility. Each company will have greater flexibility to adopt the technologies that best fit its needs, improve efficiency and more effectively adapt to the regulatory and other external dynamics. As independent companies, we will innovate and move faster as we work to improve how health care is experienced today. Finally, and importantly, simplicity. Greater independence will make it easier to serve consumers, members, patients and communities and will create opportunities for each company to pursue a broader range of partnerships. By taking this deliberate action, we are creating simpler, stronger and more focused companies.
CVS Health will be a scaled health solutions company with attractive growth and strong cash flow generation. This business will preserve a well-diversified mix of assets and capabilities to address a $2+ trillion growing market across Medicare, commercial and Medicaid. We will stay relentlessly focused on affordability, access and health outcomes. I will serve as Chairman and CEO alongside the best-in-class leadership team in place today.
CVS Pharmacy will be the national leader in pharmacy and community health care. Our investments in technology and our colleagues continue to set us apart in this greater than a $500 billion market. This is an economically resilient sector, where prescription growth will continue to be driven by medical innovation and demographics. CVS Pharmacy will build on its position as the most trusted and most frequent consumer touch point in health care.
Prem Shah, currently the Group President of CVS Health, will become CEO of CVS Pharmacy upon separation. He will be supported by the experienced leaders and colleagues who reset the trajectory and reinvigorated our retail pharmacy business. With attractive growth, enviable cash flow and a strong balance sheet, CVS Pharmacy will be a unique asset across health care and retail.
Both companies remain committed to unlocking the tremendous potential of Health100, our AI-native consumer engagement platform. The mission of Health100 remains unchanged: to be the front door of health and care. By focusing on consumers, Health100 will truly change the way health care is experienced in this country. We will drive greater interoperability to remove friction from the system and engage with consumers in a way that no one else has ever done before. We believe this separation will accelerate the adoption and development of Health100 and allow us to drive innovation, improve connectivity and unlock greater value across both companies.
We expect the separation transaction to be tax-free for U.S. federal income tax purposes and to be completed in the first half of 2028, subject to customary conditions, including final Board approval, Form 10 effectiveness and receipt of customary tax confirmation. Following separation, CVS Health shareholders will own shares in both companies. We will be transparent about our progress, and we will provide additional details along the way.
I want to emphasize that we will not lose sight of the need to execute with excellence every single day and consistently deliver on our commitments to all of our stakeholders. Our purpose is clear: to simplify health care, one person, one family and one community at a time. I am confident this decision will allow both companies to better deliver on that promise and create lasting value for all stakeholders.
With that, we will now open the call for your questions. Operator?

**Operator** (Operator):
[Operator Instructions] Our first question will come from the line of Lisa Gill with JPMorgan.

**Lisa Gill** (Analysts):
David, I can't help but to think that on November 1, 2006, 20 years ago, CVS and Caremark came together. I know you were Head of Sales at Caremark at the time. So I'm sure that this is a very important date for you. But can we first start with just the timing of this and the rationale? You walked through a number of the components. But if we could just maybe better understand especially the timing aspect.

**J. Joyner** (Executives):
Sure. Lisa, good to hear from you. And yes, I do remember, 20 years ago, in 2006, talking about what we were trying to build as a very different pharmacy services company and incredibly proud of the work that we've done over the last 20 years. And as I reflect back on that, I can't help but think how much has changed since 2006 to 2026. So 20 years of change and even, quite frankly, the change that we've seen from the timing of the acquisition of Aetna. So the market continues to evolve and change. And as a company, we need to continue to evolve with it.
So in the 2 years of being in this position, I've been afforded the unique opportunity of actually thinking about this from a position of strength. It's 8 quarters of both a beat and raise and a financial or balance sheet that is on us ahead of schedule in terms of its leverage. So we're afforded different decisions based off of the strength of the business. And I think there's 2 important things that I would point to. One is that most of the energy over the last 2 years has been focusing on the Medicare recovery, and we're now entering our third year of that important transition. And I think you'll hear a lot of that today. But I think that actually sets the stage for the fact that we actually have what we think is a repeatable process to be able to compete effectively in that market.
One thing we haven't talked a lot about is the progress that we've made at retail. And with Prem leading the recovery effort from a business that was guiding negative 5 two years ago, to now we're guiding our third year of growth in that business, it just creates an opportunity for us to say, what is the future of this business? How should we be organized to be able to compete effectively? And I think what we look for is the integration that matters. And what we've done in the last 2 years is integrate quite a bit inside of CVS Health with both Caremark and Aetna and some of the Health Care Delivery assets that's helping us lean into value-based care.
But retail has, for the most part, for the last 2 decades, operated behind the firewall. So we've always had to negotiate at arm's length. It's run independent of the business. And I think the timing of this decision is saying now is the time because we are not doing anything out of a distressed decision. We actually are doing it because we actually have healthy balance sheets with appropriate capital allocation opportunities and momentum in each one of the businesses that we're operating. So again, I feel really good about the timing, I feel really good about the decision, and I feel equally as important about the team that's going to allow us to execute against this plan.

**Lisa Gill** (Analysts):
David, if I can sneak one more in, just on the quarter and on Brian's comments on 2027, and that's 340B. I understand it's incorporated in the way you're thinking about '27, but really just want to understand 2 things. One, is this a change in the way that you're contracting? And two, Brian made the comment that you have line of sight that it ends in '27, it doesn't spill into '28. Can you maybe just help me to understand that when I think about what's happening here and why you have line of sight that it's only going to have an impact here in '26 and '27?

**J. Joyner** (Executives):
Yes. It's a great question, Lisa. And I know there's been a lot of topics since our last earnings call on 340B, which is why we tried to size it as we head into '27. So maybe I'll have Brian speak a little bit about how we're thinking about HSS and then specifically 340B. And then I want to have Prem speak a little bit to how we have our arms around and how we're thinking about specifically the 340B business. Brian?

**Brian Newman** (Executives):
Sure. Thanks, David. And Lisa, thanks for the question. As I think about the quarter itself, and then I'll progress on to '27, performance in HSS, Lisa, was in line with our expectations. And you asked specifically about PS and 340B, both 340B and rebate guarantee performance, we saw no surprises from our expectations. So we also continue to see strong performance in specialty in the quarter. We maintained our guide for the full year, so not expecting any surprises balance of the year.
I'll comment, since it's in the segment, HCD as well was consistent with our expectations, and we continue to see Oak Street perform quite well. As we thought about next year, Lisa, and looking ahead to '27, I thought it was important to establish a floor for the HSS segment, and that's effectively what we've done today. We're confident that we would deliver at least $7 billion in HSS AOI next year. That includes the discussions around year-over-year decline in 340B next year and the impact of lower Caremark membership, those 2 elements. And so it also includes tailwinds from continued strength in specialty as well as the second year of improvement in HCD as we make progress towards our path to profitability at Oak Street, et cetera.
So confident in our ability to manage the near-term dynamics, Lisa, and expect '27, as I mentioned previously, to reflect trough earnings for the segment as we return to growth in '27 (sic) [ '28 ] as we look downward.
So Prem, do you want to color that up?

**Prem Shah** (Executives):
Yes. Thanks, Brian. And David, first off, thank you for the opportunity to lead CVS Pharmacy upon separation. It's an incredible opportunity, and I just want to thank David and the Board for that.
When you think about the HSS segment, as Brian said, Pharmacy Services in the quarter was in line with our expectations, and we continue to feel good about our outlook for the remainder of the year. As you look into 2027, we're also confident in our position and our ability to manage through the transitory dynamics that we discussed prior. And coming out of the last call, I think there was 2 areas, 340B was one and the selling season was the second that I want to take a few minutes to really spend a little bit more time on.
So with respect to 340B, we do not expect this to be a topic we need to discuss going forward. The level of contribution that we have in our 2027 plan is an even smaller portion of the HSS segment earnings than it has been historically. And I would also reiterate that it's an important program relied on by safety-net hospitals and covered entities across the country, and we don't expect the program to go away fully in the future. Secondly, when you look at the 2028 selling season, we're headed into the season with confidence. If you look at what the value proposition for Caremark has and has always been, it really starts with our industry-leading cost of goods, our customer focus and our sophisticated capabilities and our pricing model flexibility that we offer to our customers that it really address their top concerns and priorities, which is affordability, transparency and experience.
Recall that 2026 for Caremark was an incredibly strong selling season. We achieved approximately $6 billion of gross new wins. And as Brian said, a portion of the membership declines we expect in 2027 reflect strategic business decisions from our health plan clients, including what you saw in Aetna's PDP book, which are not a reflection of Caremark's offerings that we have in the marketplace. And we expect the 2028 sales season and the new business pipeline to be robust, and we remain confident in our position and the value proposition that we're providing into the marketplace.
And finally, we have an incredibly strong and robust CVS Specialty Pharmacy business that's focused on the patients that we serve, but more importantly, the payers that we serve. Specialty continues to be a main driver of cost trend for our customers. We continue very diligent in driving competition and creating value for our payer partners. And it's an area that we've invested a lot in technology and AI. We continue to make the consumer experience seamless. We continue to really drive an integrated and a very strong offering there for the patients that we serve.
So overall, I would just summarize this with we expect 2027 to represent trough earnings of at least the $7 billion and for our Health Services segment, and we're going to return to growth thereafter.

**Operator** (Operator):
Your next question will come from the line of Justin Lake with Wolfe Research.

**Justin Lake** (Analysts):
I wanted to understand the impact of the breakup on the balance sheet and capital deployment opportunities. Specifically, I assume the rating agencies are now going to look at CVS Health as a managed care organization, meaning debt to cap versus debt to EBITDA. I wanted to hear how this might impact your leverage versus today.
And then we've all been expecting significant share repo into 2027 and beyond. Is there any impact on the company's ability to deploy capital versus that $35 billion of deployable capital opportunity you discussed at the Investor Day kind of post the breakup?

**J. Joyner** (Executives):
Yes. So thanks, Justin. I'm going to let Brian speak to this, but I do want to just remind everybody that as we split CVS Pharmacy, the expectation is that we will have solid investment-grade positions on both of these companies. And it speaks to the strength of each one of the businesses that remain, and our confidence in the balance sheet, and the ability to have the appropriate capital allocation flexibility. So Brian, do you want to...

**Brian Newman** (Executives):
Yes. Thanks, David. And Justin, it's a good question. And obviously, I've spent a lot of time on the leverage, both together and some of the parts as we think about the business. And I can say with a high degree of confidence that both companies will be solid investment grade with strong free cash flow generation. As you mentioned, we'll target leverage or debt to cap metrics that are appropriate for that rating level. We'll bring you along on the process, Justin, as we move throughout the next 15, 18 months.
You asked about share repo as well. I can tell you, we basically have a history of generating cash. You saw that in the guide. We raised our cash $4 billion, and my expectation to get back into the market here in the fourth quarter with the share repo program. So as we think about restoring that leverage ratio and targets, we're ahead of schedule. As I look out to the future and the transaction, I wouldn't see anything getting in the way of our ability to deploy capital going forward.

**Operator** (Operator):
Your next question comes from the line of Michael Cherny with Leerink Partners.

**Michael Cherny** (Analysts):
Maybe to dive a little bit on FutureCo. As you think about the business, there's clearly been numerous instances where CVS Pharmacy and Caremark made each other better. I'm thinking of the expansion and creation of Maintenance Choice among other different areas. How do you think about the potential, I don't want to call them dis-synergies specifically, but the strategic rationale for the overlap going forward between the 2 entities, and how the competitive differentiation that both entities have been able to generate by being together, by being aligned between the store and the PBM that they don't lose that capability going forward?

**J. Joyner** (Executives):
Yes. It's a great question, Michael, and something we've given quite a bit of thought to, because we do think that there's something unique between CVS and Caremark and even the role that Aetna plays in terms of engaging the pharmacists and the delivery of care. But the unique products that we've built over the last 20 years are things that are going to be preserved in commercial agreements between the 2 organizations. So we don't need the integration of -- in an operating structure. We need to make sure that we're aligned around where we believe that there can be value creation and make sure that there's an appropriate commercial agreement in place to support that. So that is in large part what we will be working on over the course of the next 15 to 18 months.
It is why the mail service is actually inside of CVS Pharmacy, because we have reinvented how pharmacy is delivered. So it's not the traditional mail order and retail. It is basically a 90-day supply focused and organized around how the consumer wants to get their medication. So we can choose to deliver it to the home, they can pick it up in the store, they can come through something maybe as convenient as a drive-through, but the idea is that we're organizing pharmacy around the consumer, and that Caremark gets the benefit of partnering with a company like CVS Pharmacy that continues to push the envelope on ways in which to better engage the consumer.
The thing that we've spent more time on as opposed to the products that we built in the past is where we're going in the future. And that is the emphasis around the technology platform of Health100. It will be the connective tissue between the 2 organizations, because CVS Pharmacy becomes the engagement engine. It's the most heavily transacted health care service. And as a result, more frequent transactions and a higher engagement rate with the consumer.
And what Aetna and Caremark bring to the table is all the financial information to help make more informed and better decisions around their health care. So you connect those 2, which both organizations are committed to, and we think we will build a world-class consumer engagement platform to be able to help take advantage of where we believe and see technology going and also being able to democratize the data that we know is an important part of where health care is headed.
So I think the most important takeaway is that we've given a lot of thought about what's unique that needs to be organized in a certain way, which is why mail services at CVS retail. And it's why we need to focus on the commercial agreements, so we have the sustainability and the durability of being able to continue to organize and service the consumer.

**Operator** (Operator):
Next question will come from the line of Elizabeth Anderson with Evercore.

**Elizabeth Anderson** (Analysts):
Maybe one for you, Prem. I appreciate the comment you gave about sort of the ability for the 2 organizations to continue to work together going forward. Prem, where do you see sort of additional opportunities or additional sort of areas you could focus on for the stores going forward as an independent entity that were not available to you sort of in the current form?
And then two, maybe, David, could you just comment on where you see sort of trend overall? You talked about obviously pockets of strength in MA, but any more details you could provide on that to just continue to understand the improving strength there?

**J. Joyner** (Executives):
Yes. Perfect. Thanks, Elizabeth. And I'm going to have Prem speak to where the future opportunities are. But I think it's worth noting what we've done over the last 2-plus years to get ourselves in a position to go build new products and services and create new opportunities. So Prem, if you could just take a second talking about your priority and why we're in a growth mode at retail and what gives you confidence that we're going to expand into new areas?

**Prem Shah** (Executives):
Yes. Thanks, David. And Elizabeth, thank you for the question. This is an incredibly exciting time. And if you look at our retail business, if you look back, and I go back 3 or 4 years when we started to talk about the changes, the intentional changes that we're making here. Historically, that was focused on really 3 things. First and foremost, we invested in the technology platform to create better experiences. And if you think about just some clear examples, AI now supports our pharmacy workflow for 85% of our prescriptions.
Second, we invested in our colleagues. We know that our 30,000 pharmacists, we know that our 200,000 store colleagues are essential components to deliver health care locally, and we know that health care is done by humans in our local communities, and we have a tremendous focus on ensuring that our colleagues are enabled and successful in everything that they do. And lastly, I think some of the things that we focused on around customer NPS, so the customers that walk in our stores, how do we really improve that experience for them, how do we make that omnichannel, how do we make it consistent across the board. These are 3 areas we've really spent a lot of time focusing on.
And you can see that flow through in our results in this quarter, right? As you saw in the quarter, our comp scripts grew 3.9%, but also we were also able to take advantage of new opportunities. I think GLP-1s is another great example. Our scripts in GLP-1s this quarter grew 23%. And it's because we took action, we made access more affordable. We made it easier for patients to show up. I mean, we really drove focus on what's most important for the people walking into our stores.
And then lastly, I think it's really important to talk about our evolution of the reimbursement model. We focused on that over time with CVS CostVantage. And let me just be really clear, the CVS and Caremark relationships have operated behind a firewall for more than 2 decades. So this is something that we continually do. But we continue to be focused on the value proposition that we create to payers.
And as I look forward, I think the excitement I have in our CVS Pharmacy asset is we have a well-run, strong service offering for the customers we serve. We're in a position now to offer incremental health care services, leverage our 9,000 stores, leverage our footprint in very different ways, because the key thing for almost all payers, I don't care who you are in this country, is we have a challenge with affordability. And CVS Pharmacy affords and has the privilege to serve in every community, standardize health care services and transform the industry in terms of what we can do, and this will afford us the right to really drive this forward into the marketplace.

**J. Joyner** (Executives):
That's perfect. So Prem is effectively running America's pharmacy. And we say this all the time, we think this country needs CVS Pharmacy and the community-based services that we're providing, because we are investing in the communities, and we're going to continue to extend that reach as we go forward.
And now if I could just speak to the remaining CVS Health organization and, to Prem's point, about this focus on affordability, we think the focus will now be purely on what we believe are the drivers of health care in this country. And if you look at 2/3 of the spend coming from both the health systems and the drug manufacturers with increases that, in most cases, are high single or low double digits, there is a significant opportunity for this organization to tackle that challenge on behalf of the customers which we serve. So we are declaring that the company that will remain will be focused to support the payers and bring affordability and improving access.
So Steve, do you want to just give a little bit of color on the trend environment and how we're looking maybe just on Medicare as an example?

**Steven Nelson** (Executives):
Sure. So thanks, David. Good morning, Elizabeth. So look, Aetna has had a strong quarter, as we've talked about, really nice progress across all the businesses at Aetna, as we return the business to target margins. But I'll just specifically comment on Medicare. We have seen some pockets of favorability. Continues to be a high trend environment generally. But as we've laid down the foundation for this business over the last couple of years, we've seen tremendous improvement, and we're going to build on that.
We took the same discipline into our 2027 pricing, assumed trends remain elevated and the priorities were unchanged. We were going after one more year of margin improvement, and we pulled several levers to achieve that. Obviously, as you could see, we did make some adjustments to benefits. But beyond that, we made adjustments to our geography, our product mix. We brought leading star scores in the 2027 payment year. We made adjustments to our network. So we had the highest performing providers in the markets where we wanted to perform. And we've built robust capabilities around medical cost management. So all those levers we were able to put into place as we think about 2027.
And just a little insight here, early into AEP, but so far it's playing out exactly as we expected. We'll be able to give more color to that as we complete AEP. But this business is performing really well, and we expect another year of margin improvement with some modest growth actually. The benefit stability we're able to put into the marketplace is, I think, going to be important as we think about high retention of our current members. That helps engage the members, creates actually better health care costs and a higher satisfaction.
So I really like the position of the business. We have more work to do, still a high trend environment, but we're lining up a lot of capabilities at Aetna with our investment in technology and the tools we're putting into place. We really think we have an opportunity to impact the affordability and access issue that is so much needed in our health care system.

**Operator** (Operator):
Next question will come from Erin Wright with Morgan Stanley.

**Erin Wilson Wright** (Analysts):
So can you speak to the rationale for retaining specialty at CVS Health, and how you see the long-term drivers and synergies playing out, as also alongside kind of the PBM becomes more stable, more of a fee-for-service business over time. I guess, do you see opportunities to further lean into specialty as that becomes a larger component of RemainCo or CVS Health?

**J. Joyner** (Executives):
Yes, it's a great question, Erin. And I think you're hearing 2 things from the remaining CVS Health organization, and that is the focus on affordability and access, and it also is the role that we play in trying to tackle those challenges for our customers. And Steve just talked a lot about Medicare. It is a growing part of the business as we have an aging population, and we believe that there is an important step from moving from a fee-for-service operating environment to value-based care. So that piece is a heavy investment for the business, and we need to make sure we have the appropriate assets that create the synergistic and the value prop for how we're going to tackle those unique high-acuity populations.
The same thing holds true on specialty. And we've talked for a long time. I started in 1993 with Caremark. It was leading the part of how specialty integrates into the PBM. And if I fast forward 30-plus years later, there is 2% of this population that's driving more than 50% of the spend of pharmacy. And it is growing at a rate that's not affordable, and it's not sustainable. And so it is why you need all of the levers of a classic PBM in order to continue to attack the rising drug cost and the way in which we create competition. And so we think the synergistic opportunity with the PBM and specialty remains intact because that is, again, one of the most important priorities for the customers that we're serving. And so that is part of the logic of keeping it together.
And then as I look specifically at the integration that matters, which I mentioned on the front end of the call, this has been a really interesting 8 years in terms of bringing the businesses together. And what Aetna has been able to gain through the combination of the assets is a world-class PBM. So Aetna is far more sophisticated and far more effective in managing their pharmacy benefit in addition to total cost of care because of the assets that Caremark and our specialty business brings to the table.
And on the flip side of this, Caremark has been far more effective in terms of thinking about the role of pharmacy and how it impacts the total cost of care, because it's outside of just the pharmacy benefit and it is the role that actually medications play in managing the total cost of care, of which Aetna is managing the total risk. So there has been really interesting and I think evolving integration opportunities between the businesses. And I expect that, that will continue as we find new markets and new opportunities.
And this is, in large part, delivered to both our Medicare population and equally as important to the commercial platforms and franchises that we have across both Aetna and Caremark. And lastly, Medicaid becomes very complementary to the business because these are high-risk populations and actually in markets that complement the roles that we're playing with Medicare and even the providers that we're working with across commercial.

**Operator** (Operator):
Next question will come from the line of Stephen Baxter with Wells Fargo.

**Stephen Baxter** (Analysts):
You've touched on, I guess, the capital and strategic parts of this. But if we think purely about the operating cost structure, we can look back to the original Caremark and CVS transactions or the more recent CVS Aetna transactions and just see that operating cost synergies were a big part of the financial rationale of those deals. I know it's early, but I guess, how are you thinking about what the potential financial dis-synergies could be? And any color on whether you think they'll sit entirely in the newly created CVS Pharmacy business or, I guess, shared or allocated across the 2 businesses?

**J. Joyner** (Executives):
Yes. So let me start, and I'll let Brian finish. So we obviously are contemplating some onetime costs. So that has been contemplated in our guidance and how we're thinking about the future, but we feel like these are all manageable. And as we look at the opportunities that we've been describing on today's call, we think this will more than offset some of those expenses. So Brian, I don't know if you have anything else to add.

**Brian Newman** (Executives):
Yes. Thanks, David. Stephen, I'd just offer that when we looked at the deal, the strategic value created by taking this action is going to far outweigh any dis-synergies. As I look at the run rate AOI impact of any stranded or public company cost as well as any onetime costs, they're certainly manageable and in line with other transactions of this type. So we're going to look to offset any run rate costs over time, including pursuing opportunities created by a simpler independent structure that David referenced earlier. As you said, it's early in the process. So expect us to come back with more details as we progress through the separation, but I'm confident that we certainly can manage any dis-synergies there.

**Operator** (Operator):
Next question will come from Andrew Mok with Barclays.

**Andrew Mok** (Analysts):
Just wanted to make sure I understand your 2027 EPS outlook of $8.65 in the context of all of today's results and announcements. So given the $0.20 raise to this year's EPS guidance, it doesn't look like you're assuming much EPS contribution from the resumption of share repurchase in 2027. Can you help us understand that dynamic and whether there are any other offsets embedded in the outlook, including breakup costs you might incur next year?

**J. Joyner** (Executives):
Go ahead, Brian.

**Brian Newman** (Executives):
Yes. So you're reading it right, which is we took the guide this year up $0.20 and effectively flowed that through. We had talked about an $8.44 floor next year. So now it's $8.65, rounded up $0.01. So we're at $8.65 next year. That only assumes the offset of dilution in share repo. So as you can imagine, as cash is back, leverage is where we want it to be, we've got some dry powder to leverage. So net-net, what's implied in the guide next year where we set a floor is just the offset of dilution. Hopefully, that answers your question.

**Operator** (Operator):
Next up will be Ann Hynes with Mizuho.

**Ann Hynes** (Analysts):
I know that you said 2028 should be on the higher end of your range you provided at Investor Day. Are you ready to give any kind of growth algorithms, whether on operating income or EPS for the 2 new companies on a stand-alone basis?

**J. Joyner** (Executives):
Yes. Go ahead, Brian. We're not really guiding beyond '28 at this point. And Brian...

**Brian Newman** (Executives):
Yes. I was thinking back to Investor Day, and we set out a road map, which was in the mid-teens, which gets us to the 2028 horizon. We're tracking well against that. We always talked about multiple paths to get there. I think the businesses are performing very well. We just took '26 up again. That's $1 over where we started. We just put a floor in for '27. And by signaling that we're going to be at the upper end, in the upper end of mid-teens by '28, I just wanted to give the Street confidence that we're on track to meet or exceed our expectations. Well, we'll come back to you on the February call and we'll talk more about the details around the '27 guide and that will give you a firmer base.

**J. Joyner** (Executives):
Yes. So I mean this all is a timing issue. We gave headwinds and tailwinds early last quarter than we normally do. And so we'll be back in February with more clarity. And maybe just a reminder, in case people are questioning this, we are doing this out of a position of strength. We don't have to make the decisions. And so as we're looking at the business and how it's performing, we have confidence, and we're actually doing this because we believe this is the right thing to do for the long-term growth of the business, not because there's any issue that may be on the horizon in '28.

**Operator** (Operator):
Next question will come from Scott Fidel with Goldman Sachs.

**Scott Fidel** (Analysts):
Wanted to just go back to the margin improvement and expansion that's been sustaining over at Aetna, and where you are specifically in that journey. Clearly, Medicare Advantage being the particular driver of that. It seems like at this point, based on your updated guidance, you probably breached into getting towards, I would think, sort of a very low level of profitability back in the Medicare Advantage business for 2026 inside of the guidance. Just wanted to confirm that.
And then I know, Steve, you mentioned how, I think you said another 1 more year of sort of focused sort of margin improvement targeted for '27. Should I read into that anything in terms of where you expect to take the margins for '27 back towards target? Or is this still a multiyear journey in terms of getting back to that 3% to 4% target margin for Medicare Advantage?

**J. Joyner** (Executives):
Steve?

**Steven Nelson** (Executives):
Sure. Thanks. Yes, I can confirm the business is still on its multiyear journey, but it's ahead of expectations. We are moving into the profitable territory in '26, so I can confirm that. And then as we look to '27, we're going to expand on that for the reasons I indicated earlier. Just maybe a couple more thoughts as we think about the business and why we're so confident in the margin expansion in '27.
Beyond the levers that I talked about, the repositioning of sort of holistic Medicare. So as we think about -- our Part D stand-alone was performing well, we did a reset there. That's going to contribute our group Medicare Advantage business. We talked about that as we got through 2027, we would have about 75% of the book repriced. That's very much on track. And so holistically, as you think about it -- and then as I said, we were able to add stability, so we'll be able to see some modest growth in the areas that we want to see that growth. And so all this kind of comes together just as we hoped and we planned for and strong execution by the team. And so really proud of where we are. It's positioned nicely to go into 2027 with another year of nice margin expansion.

**J. Joyner** (Executives):
Great. Thanks, Steve. All right. Operator, I think we have time for one more question.

**Operator** (Operator):
Okay. Your last question will come from George Hill with DB.

**George Hill** (Analysts):
I guess, David, just to kind of round this out, I would ask, as we think about the future split up, kind of what changed? And I guess, could you talk a little bit more about like what changed in the outlook in health care from a year ago versus where you are now? And could you talk about like how you saw each business kind of -- like what was competitively disadvantaged and what becomes competitively advantaged through the split up? And I'll end it there.

**J. Joyner** (Executives):
Yes. George, thanks for the question. Maybe I'll end the way I started. Two years ago, when I took this job, we didn't have the ability to make decisions like this because we were struggling on our Medicare business. PCW was guiding down 5%, and we were focused purely on running and operating this business against what we knew we were capable of doing. And so I've looked 2 years later and the say-do ratio that Brian has been so consistent on in terms of making sure that we underpromise and overdeliver, and we've been 8 quarters of delivering on that. And so what's changed in 2 years is the fact that we now can look at this business and the assets that are assembled and really determine without any distress or without anything that we have to do on what is the right strategic decision to make.
And so as we said, CVS Pharmacy has been operating behind the firewall for the last 2 decades. It's always been an arm's length negotiation and structure, which again just reinforces the fact that there are integration opportunities, but nothing that we can't solve for with the commercial agreement. But what's powerful and where we see health care going is in the area of technology. And so how do we make sure that we capitalize on this next wave of change that we know is going to be very prevalent inside the health care space and make sure we leverage everything that we actually have in this current enterprise and preserve it for the future.
That's why we're spending as much time on connecting and integrating where we believe it matters. And so we're preserving the CVS and Aetna integration. We're preserving the Oak Street and Aetna and Signify. And we're also now focusing on areas that we know we can capitalize in the future around technology. So I would just say, I couldn't be happier and more proud of the team's performance that led us to a place where we can make the decisions out of strength and also the fact that we believe this is the right thing for all stakeholders involved.
We believe we're going to serve our consumers more effectively. We're going to serve our customers more effectively. And hopefully, that will actually be viewed favorably from the shareholders that are investing in this company.
So in closing, I just want to thank everyone for joining this morning. We're incredibly excited about this next step in our evolution. I want to specifically thank our colleagues across the country and across this company that work and the work that they do every day to serve our customers. Their dedication and relentless commitment to those we serve has built the foundation for everything we've discussed today.
We've taken this deliberate action to create long-term value and do even more to deliver on our purpose, to simplify health care one person, one family and one community at a time. And I look forward to keeping you updated on our progress.

**Operator** (Operator):
Thank you for joining CVS Health's Third Quarter 2026 Earnings Call. This concludes today's conference call. You may now disconnect.


---

## ④b 舊逐字稿摘錄（前一季＋投資人日；對照管理層以前說過什麼）

### CVS_Q2_2026_Earnings_Call_20260805.md
- 2026-08-05｜CEO｜guidance：CEO 宣布 2026 全年調整後 EPS 財測上調 0.60 美元至 7.90–8.10 美元。（原話："raising our full year 2026 adjusted earnings per share"）
- 2026-08-05｜CEO｜guidance：全年營運現金流預期上調至至少 115 億美元，較前次增加 20 億美元。（原話："expectation for cash flow from operations to at least"）
- 2026-08-05｜CFO｜guidance：CFO 給出 Health Care Benefits 全年調整後營業利益新區間，較前次財測增加逾 10 億美元。（原話："a range of $5.03 billion to $5.37 billion"）
- 2026-08-05｜CFO｜margin：全年 MBR 預期 89.75% 上下 25 bps，管理層稱對下半年醫療成本趨勢維持審慎看法。（原話："full year MBR of 89.75%,"）
- 2026-08-05｜CFO｜margin：管理層預期 Q1 至 Q4 的 HCB MBR 增幅略高於 950 bps（Q1 已調整前期準備金發展）。（原話："between our first quarter and fourth quarter MBR"）
- 2026-08-05｜CFO｜margin：Q2 MBR 87.4%；individual exchange 風險調整與有利前期發展合計貢獻約 5 億美元、140 bps，剔除後核心仍優於預期。（原話："approximately $500 million or 140 basis points"）
- 2026-08-05｜CFO｜margin：核心優於預期主要集中在 Medicare；Medicaid 與 Commercial 符合預期。（原話："Medicaid and Commercial businesses performed in line"）
- 2026-08-05｜CFO｜guidance：財測不假設 2026 年任何股票回購，待槓桿改善再評估資本配置。（原話："does not assume any share repurchases this year."）
- 2026-08-05｜CFO｜capital_allocation：Q2 底槓桿比約 3.5 倍，管理層預期隨 2026 展望執行持續改善；上半年僅以股息回饋股東逾 17 億美元。（原話："ratio at the end of the quarter was approximately 3.5x"）
- 2026-08-05｜CFO｜guidance：管理層提前一季給 2027 初步評論：以 8.44 美元為合理下限（與共識一致），較調整後基準 7.46 美元成長約 13%。（原話："a reasonable floor, Mike, for '27 for adjusted EPS"）
- 2026-08-05｜CFO｜margin：7.46 美元基準的口徑：取更新後 EPS 財測中點，並依指引慣例排除前期發展與已退出的 individual exchange 前期項目。（原話："This baseline reflects the midpoint of our"）
- 2026-08-05｜CFO｜commitment：管理層重申 2025 至 2028 年調整後 EPS 中雙位數 CAGR 目標（Investor Day 提出）。（原話："mid-teens adjusted EPS CAGR from 2025 through 2028"）
- 2026-08-05｜CFO｜commitment：揭露節奏：Q3 財報說明 2027 順逆風，Q4 給完整全年財測；今年將 2027 評論提前一季。（原話："we intend to share 2027"）
- 2026-08-05｜CFO｜capital_allocation：2027 資本配置假設：僅抵銷稀釋的回購，此外沒有。（原話："offsetting dilution in '27, Justin. So nothing beyond that"）
- 2026-08-05｜CFO｜risk：管理層預告 340B 市場動態將在 2027 年構成逆風。（原話："dynamics in our 340B business"）
- 2026-08-05｜CFO｜customer：管理層預期 2027 年 Caremark 會員數下滑，理由為客戶續約的審慎承保與健康計畫客戶的產品退出。（原話："we will see membership declines in Caremark next year"）
- 2026-08-05｜Prem Shah｜customer：Prem Shah 稱 2027 續約留存率略低於歷史水準、但較符合產業常態；本年新銷售逾 60 億美元。（原話："retention rate that's slightly lower than our historical"）
- 2026-08-05｜CFO｜risk：Caremark Q2 受 340B 壓力，並有原預期下半年的價值提前入帳；調整後底層符合預期。（原話："We also experienced a pull"）
- 2026-08-05｜Prem Shah｜risk：340B 壓力來源：藥廠對 covered entities 施加限制，以及大型特殊藥學名藥化。（原話："Pharma manufacturers are imposing restrictions"）
- 2026-08-05｜CEO｜competition：Caremark 預期轉向最低淨成本定價模式將加速，並提到與 FTC 的擬議和解。（原話："the transition to net cost price models to accelerate"）
- 2026-08-05｜CFO｜margin：管理層認為 PBM 長期可維持歷史水準的利潤率。（原話："our ability to achieve fair margins consistent with"）
- 2026-08-05｜CFO｜margin：Aetna 預期邁向目標利潤率需「未來幾年」；今年迄今營業利益已改善逾 20 億美元。（原話："pathway back to target margins over the next couple of"）
- 2026-08-05｜CFO｜guidance：Pharmacy & Consumer Wellness 全年調整後營業利益預期至少 64 億美元，較前次增加 2.2 億美元。（原話："full year adjusted operating income of at least $6.4 billion"）
- 2026-08-05｜CFO｜guidance：Health Services 全年營業利益展望維持不變（強勢 PBM 抵銷 340B）；企業整體區間 165.8–169.2 億美元。（原話："range of $16.58 billion to $16.92 billion."）
- 2026-08-05｜CFO｜customer：PCW 同店處方量成長 7%、同店藥局銷售約 +3%、前店銷售 +100 bps。（原話："Same-store front store sales increased 100 basis points"）
- 2026-08-05｜Prem Shah｜competition：Rite Aid 交易被稱為今年上半年的增量順風，管理層預期仍能以高於市場速度成長。（原話："Obviously, the Rite Aid was an"）
- 2026-08-05｜Prem Shah｜product：CVS CostVantage 成本基礎定價被描述為帶來更一致的藥局利潤率結構。（原話："This is also helping us get to a"）
- 2026-08-05｜CEO｜product：GLP-1 現金支付通路：MinuteClinic 虛擬減重門診 29 美元；與 Lilly 新合作，Zepbound 與 Foundayo 現金價同日取藥。（原話："MinuteClinic's 24/7 virtual weight management offering"）
- 2026-08-05｜Prem Shah｜competition：Prem Shah 承認公司進入現金支付／直接面向病患 GLP-1 市場稍慢，今年已重新調整方案。（原話："may have been slightly slow to enter the cash paying market"）
- 2026-08-05｜Steven Nelson｜customer：Medicare 2026 優於預期：會員收縮低於預期、會員組合有利；2027 投標假設延續偏高趨勢；團體 MA 已續約約 75%。（原話："We assumed a continuation of the elevated trend"）
- 2026-08-05｜Steven Nelson｜risk：管理層指 No Surprises Act 的爭議解決（IDR）流程被少數業者濫用，已納入趨勢考量。（原話："the dispute resolution process is clearly being"）
- 2026-08-05｜CEO｜risk：管理層提及正就 Arkansas、Tennessee 等州藥局相關法律提出挑戰。（原話："unconstitutional laws in states like Arkansas and Tennessee"）
- 2026-08-05｜CEO｜commitment：科技投資承諾：十年內投入 200 億美元以上，並強調審慎、看 ROI。（原話："invest $20-plus billion in our technology efforts"）
- 2026-08-05｜CEO｜product：CEO 描述公司由消費者導向健康照護公司轉為消費者導向健康照護科技事業；Health100 與 Haio AI 助理已開始限量上線。（原話："moving from a consumer-based health care company"）
- 2026-08-05｜CFO｜margin：CFO 稱透過科技效率與 AI 已累積逾 10 億美元營運費用節省。（原話："we've generated actually some significant savings"）

### 問答異常語氣（迴避／改口／保留）
- CVS_Q2_2026_Earnings_Call_20260805.md｜問：Andrew Mok 問 340B 逆風的驅動因素與 HSS 內部可抵銷的項目｜答法：Brian Newman 表示不拆分 Caremark 各價值池，也不評論 340B 規模，只指向 2027 EPS 下限與 Q3 財報再提供順逆風。
- CVS_Q2_2026_Earnings_Call_20260805.md｜問：Michael Cherny 問 2027 HSS 抵銷 340B 逆風的路徑｜答法：Brian 稱現在談 2027 細節太早，只重申 EPS 下限與 CAGR；Prem 與 CEO 轉談專科藥局、Cordavis、整體企業動能，未量化 340B 或可抵銷幅度。
- CVS_Q2_2026_Earnings_Call_20260805.md｜問：Stephen Baxter 問 commercial 風險業務今年利潤率與長期目標比較｜答法：Steven Nelson 只答 commercial 表現強勁、符合預期，未給利潤率與長期目標的數字比較。
- CVS_Q2_2026_Earnings_Call_20260805.md｜問：Justin Lake 問 Rite Aid 等份額增益正常化後 PCW 成長可持續性與每張處方毛利、CostVantage 進度｜答法：Prem 回答服務、定價模式與高於市場成長的定性敘述，未給 2027 每張處方毛利或份額正常化的數字。

---

## ④ 判斷卡（judge_card.md）

<!-- source: .claude/skills/stock-analyst/references/v16/judgment-rules-v19.md sha256:342f7c06bb0a97e9 git:8cfc0d5bd condensed:2026-09-16 model:sonnet -->

# 判斷卡（v20 judge，Opus 單輪無工具）

你是買側資深分析師＋PM決策層，估值任務＝判斷股價隱含什麼預期非預測未來值多少；好生意（獲利品質好、ROIC持續期長、護城河產業結構好）優先於好價格，好價格是加分項非前提 [§0]。輸入＝bundle全文(facts.json事實表＋最新一季逐字稿＋舊逐字稿摘錄〔前一季＋投資人日〕＋本卡＋archetype條件載入段)，之外不開。舊逐字稿摘錄用來對照：管理層以前的財測與承諾，最新一季做到沒、有沒有改口；落差寫進 contradictions[] 或 thesis.R[]，引用時寫場次日期＋講者。
只在五個出手點落判斷：①論點與唯一致命數字②護城河方向與再投資報酬③情境樹假設④反證裁定⑤決策輸入與行動條件，其餘程式投影，填了即FAIL。承重數字引`fact_refs[]`(詳共用約定)。

---

## ①論點與唯一致命數字

**問一｜怎麼賺錢**（`answers.q1_business`）：判斷句＝賺誰的錢、錢卡在哪一節點；營收分部＋最新一季毛利率/營益率為最小交付，>10%營收分部為起點。`industry.clock_phase`(必答)：I復甦/II擴張/III過熱/IV收縮＋一句依據(非股價)。供需durability(必填一句)：結構性持久/週期性將反轉/供給可逆性高，餵bear機率。議價權寫「錢卡在哪一節點」，爭點時逐條列供應商客戶(top3供應商>70%或前1-2客戶>40%必列)。⚑單點依賴必答：護城河證據或集中度風險。`industry.tam_table`(條件式，低滲透/份額擴張/新品類/利潤池遷移時展開TAM/SAM/滲透率/段CAGR/OI池占比5年前→現，未展開見共用約定)：硬接線OI池5年淨流出≥5pp→問三Runway降一檔 [§2問一]。

**`thesis`（假設與風險，唯一居所）**：持有期決定訊號或噪音(<6個月財報權重高；>2年護城河趨勢與ROIC方向為主)。H1/H2/H3各含①數字門檻②信息來源③漂移觸發，禁延用上份；期限填`2y`/`5y`/`10y`(其餘`null`)，長期論點需長期證據。漂移分級(TTM偏離)：2Y連2季≥5%削弱/連3季≥10%反轉；5Y連4季≥5%削弱/連6季≥10%反轉；10Y跨2年度削弱/跨3年度反轉。R1/R2/R3：⚡短期(1-2季，連2季即減倉)/🔥中期(4-6季，連4季才大動作)/🐢長期(2+年，≥50%機率才砍倉)，`clock`只填⚡/🔥/🐢一值。Single Thing：1個binary discrete event，五格(描述/為什麼致命/如果發生/如何監測/12-24月機率)，唯一居所 [§5]。

**必答項**：`industry.clock_phase`、供需durability一句、`thesis.H1-H3`、`thesis.R1-Rn`、Single Thing五格。

---

## ②護城河方向與再投資報酬

**問二｜競爭優勢**（`answers.q2_moat`）：判斷句＝`moat.trend`；一條機制＋可證方向(對最強同業ROIC spread，或最大客戶份額方向)，取不到換可比軸(份額/留存/ASP)。二維評分(execution/pricing power各1-10)→`moat.grade`：10=S、9=A、7-8=B、5-6=C、<5拒絕；SaaS/銀行/保險/寡占公用允許「綜合分+narrative」。威脅三級(落`moat.threats[]`)：🟡點對點不扣分；🔴生態攻擊−1分；⛔架構替代−2分且thesis重評。合併分≥8需同業ROIC spread為正且擴大/持平(連2年收窄仍≥8需反駁否則強制−1)；破壞性競爭→威脅機率下限30%。`moat.trend`(execution/pricing power各判擴大/穩定/縮減→↑/→/↓，禁寫「持平」)：領先玩家最大客戶份額下滑(sourced)→不得標↑；`moat.trend`=↓且等級≤B→Hard Veto(迴避) [§2問二]。

**§5.R報酬持續期**(全文見archetype條件載入roic-durability.md)：`moat.roic_durability`含當期ROIC(稅後營業利益率×投入資本周轉率)＋四檢查點`checkpoints[]`(需求基礎值/決策層級/價值鏈分配/社會容忍度，鍵名`item`/`level`🟢🟡🔴/`text`，缺一FAIL，社會容忍度🔴入反證紀錄)＋再投資空間`roiic`/`reinvest_rate`/`endo_ceiling`(內生成長率＝增量ROIC×再投資率；再投資率＝`(Capex−D&A+ΔWC+收購淨額)÷NOPAT`) [§2問二]。

**問三｜成長**（`answers.q3_growth`）：判斷句＝`growth.runway_post_y5`；成長是量/價/併購/回購一句、三年共識EPS CAGR(家數來源，落`eps_meta`)、內生上界引§5.R為最小交付。缺口＝共識CAGR−內生天花板，歸因margin擴張/淨回購/收購/無法歸因(→加註「依賴re-rate」，信心上限「中」)。GAAP CAGR＝`(FY+3E÷基期)^(1/3)−1`，禁機械外推。Runway：現有成長率幾年達30%滲透率→`runway_years`；≥10年高確信、5~9年中等折扣、<5年倍數保守 [§2問三]。
- `runway_post_y5`(必填燈號)：🟢寬＝滲透率≤35%或有sourced下一條S曲線；🟡中＝35-70%且無第二曲線；🔴窄＝>70%或已見頂無第二曲線。硬接線：🔴→持有年限≤3Y警示+Soft Veto(≥觀望)；🟢為row 8a必要條件並觸發「10Y二段延伸」必填 [§2問三]。
- 衰退信號十類(落`growth.decay_signals`)：毛利率連2季YoY下滑｜核心市占近12個月縮減｜主力產品提價後銷量下滑｜EPS CAGR顯著高於Rev CAGR(差>5pp)｜FCF/NI<0.75連2年｜SBC/Rev>5%且逐年上升｜TAM萎縮或被替代技術壓縮｜產業估值倍數近3年系統性下移｜maintenance capex占FCF>60%｜停止投資新產能且收入3年內下滑。亮燈數→兩評級：價值陷阱風險0個🟢/1~2個🟡/3~4個🔴/5+個⛔；長期成長性🟢(信號0)/🟡(1~2)/🔴(≥3)；`trap_analysis.verdict`必給🟢/🟡/🔴，依據寫反證紀錄。留存經濟(擇一口徑，爭點才展開)：降且dual-track自動升🔴。AI取代風險：🟢=品質分9/🟡=6/🔴=3。`growth.segments`(mix決定利潤時展開，未展開見共用約定) [§2問三]。

**必答項**：`moat.trend`、`moat.grade`、`moat.threats[]`、`moat.roic_durability`(含四檢查點)、`growth.runway_post_y5`、`growth.decay_signals`、`trap_analysis.verdict`。

---

## ③情境樹假設

`scenario_inputs`（EPS路徑五年、終端倍數、機率、yield、second_stage、Max DD範圍與依據）——你不寫`scenario.json`，那份由程式跑`dd_scenario.py`產生。**估值口徑由程式決定（2026-10-12）**：事實表`f_consensus_eps_fy1`≤0（虧損）→尾段給`sales_multiple`形狀，情境樹改填營收路徑×終端EV/S：`start`={`rev`=`f_rev_consensus_fy1_m`、`ev_s`=`f_ev_s_fwd`、`basis`}，`rev`五年路徑(百萬)、`ev_s`終端EV/S、`net_debt_y5`/`shares_y5`(終端淨負債/稀釋股數，須反映該情境的現金燒耗、再融資與增資稀釋；null=沿用目前`f_net_debt_m`/`f_shares_diluted_m`)；終端每股價=max(0,(營收×EV/S−淨負債)÷股數)，Bear債務吃光股權就讓它歸零。此模式不填`eps`/`pe`/`second_stage`；Bear/Base/Bull散布、機率、Max DD、年期規則照舊，「EPS分母同源」改為「EV/S分母(FY+1或終端年營收)與現價EV/S同源」，三分量拆解改看「每股營收複利/EV/S變動」，倍數貢獻≥Base合計IRR的40%同樣標「估值依賴型」。Bear機率5Y不應<20%(多數25-30%；極強護城河+短期已兌現才壓15-20%)；Bull/Bear散布5Y應比1Y/2Y寬≥50%；Base機率不應>50%；bear機率須註明依據，sourced結構性durability仍硬套bear需說明「為何不採信」否則不得高於base [§3]。
- 內生天花板sanity check：Base情境EPS CAGR貢獻vs§5.R內生天花板(同組數字不重算)→天花板內✅/超出⚠(⚠→Bear機率強制≥30%)。成長熄火：3年後成長率降至15%/10%/5%三情境×Forward P/E壓縮→估值跌幅，作Bear PE錨。三分量拆解(≤80字，Base IRR多少來自EPS複利/re-rate/股息淨回購)：re-rate貢獻≥Base合計IRR的40%→標記「估值依賴型」(`decision_inputs.valuation_dependent=true`) [§3]。
- IRR落點：<8%/yr弱、8-12%中、>12%強、>15%罕見，不作跨檔排序依據。AR=`(P_bull×|Bull5Y%|)÷(P_bear×|Bear5Y%|)`，<2平庸/2-4偏正/≥4顯著，非放鬆機率防線理由。年期硬規則：①表頭終端年=主時距終端年②終端倍數EPS分母年期與現價倍數同源③終端倍數必附≥1個同業現值comp對照 [§3]。10Y二段延伸(`runway_post_y5`=🟢且終端倍數承重，或Base IRR實質來自Y5後)：Y5→Y10 EPS CAGR/10Y累積倍數/IRR。R:R數學假象：下行>15%正常使用；5-15%警示「已接近定價」；<5%失效標「數學假象」禁引用進場判定，改極端Bear(Bear PE×0.8+Bear EPS×0.85)重算(Bear EPS=FY+1 EPS×0.9；Bear PE=成長熄火「降至10%」情境) [§3]。

**Max DD**(`premortem.max_dd`)：填範圍`lo`/`hi`(禁單點，寬度≥10pp)+`path_risk`(🟢0～−30%/🟡−30～−50%/🔴<−50%)；推導依據須寫`reasoning.premortem`。硬接線：🔴且thesis脆弱(`moat.trend`↓或`runway_post_y5`🔴或估值依賴型)→倉位上限下修(6%→≤3%)；🔴但thesis完整→不因波動砍倉，註記「深回撤心理準備」[§2問六]。

**必答項**：`scenario_inputs`三支EPS路徑、終端倍數、Bear/Base/Bull機率、`premortem.max_dd.lo/hi`、`path_risk`（sales_multiple模式：三支營收路徑、終端EV/S、淨負債、股數，其餘同）。

---

## ④反證裁定

**`premortem.blind_spots[]`（反證唯一居所，違例即無效輸出）**：每條`view`(擇一)｜`evidence`｜`assumption`｜`consequence`｜`ruling`(採納或反駁+理由)｜`watch`(＋`evidence_refs`)。三視角(enum)至少各一條：`論點失敗`(5年後虧50%最可能的故事)／`論點成功但股東經濟變差`／`價格已反映太多`；不適用寫`not_applicable_reason`。steelman、自我攻擊(寫檔前一次inner monologue「最強3個反駁點」，觸及核心論據者併進本紀錄)、trap判斷依據一律引用本紀錄不重寫(`trap_analysis`本欄只交`verdict`🟢/🟡/🔴+`label`，`evidence_for/against`不要填)。視角①與Single Thing對帳(撞上不動/部分重疊回補/獨立則重寫)。**降位不得安靜刪門檻**：前份反證帶指標門檻，本輪降位仍須保留「指標＋門檻＋資料來源」，取不到值標「資料缺口」，確實不成立才退休並在`contradictions[]`寫理由 [§0.5(一)][§2問六]。

**`contradictions[]`**：先列一致判斷，再列矛盾(矛盾點/A側/B側/性質：可調和=程度差異、不可調和=方向相反)；⚖不可調和矛盾必填裁決：選哪邊/依據(非「直覺」)/硬數據點/執行路徑(≥1 if-then＋1反向條件，動作具體如加碼至X%/清倉，禁「再評估」)；Steelman義務：觀望迴避寫「現在就買的最強論證」，進場寫「現在就賣的最強論證」。前份漂移歸因：`drift_watch`20欄按`cause`三選一(`價格變動`/`新證據`/`方法變動`)分組，`prior_field`填涵蓋欄名陣列，漏一欄＝FAIL；門檻或Single Thing與前份不同須歸因「舊→新＋理由」，`rearm_trigger`不得寫「相同」；觀望須點名binding constraint，`rearm_trigger`=該約束的否定，多因素模糊觀望=重寫 [§5]；前次觀望/迴避且報酬>+30%須明寫翻面理由；前份在90天內：`decision_inputs.qc49_inherit_prior`答一題——前份觸發器全部沒發火填`true`，有任一條已發火填`false`並在contradictions引用那條；`prior_verdict`／`prior_role`由程式帶入，不要填 [§4]。

**負向證據強制處置（硬擋）**：`findings_digest[]`每條`direction="-"`的finding必落於`contradictions[]`/`blind_spots[]`/`triggers[]`/`moat.threats[]`/`thesis.R[]`之`evidence_refs`，或寫進`evidence_dismissed[]`(`{"ref":…,"reason":…}`，理由需指出證據本身問題，禁「影響不大」)。`triggers[]`每列`n`/`text`/`type`/`maps_to`/`metric`/`threshold`/`action`/`source_freq`/`date`；type僅八值(假設驗證/風險/Single Thing/估值rearm/加碼/減碼/清倉/複審日期)，H1-H3或R1-R3寫`maps_to`不塞`type`。`kill_metrics[]`陣列，每條`metric`/`bear_threshold`/`window`＋`source`；`rearm_trigger`=估值rearm/進場首倉列；`catalysts[]`type英文六值`product`/`regulatory`/`capacity`/`guidance`/`macro`/`other`(禁中文)。QC-39產業態勢三軸(必填一句)：A競爭惡化/B結構轉好與durability/C其他結構變數(法規/關稅/反壟斷/通路/商模/替代技術/客戶結構)→裁決=競爭惡化中/結構性轉好中/其他結構變動中(指名哪軸)/雙向拉鋸/靜態＋一句sourced依據，禁只報單向 [§6]。重大事件：M&A(>市值5%)/集體訴訟/臨床或FDA讀數/CEO或CFO離職或SEC調查/客戶流失皆🔴，涉核心假設或護城河須入`thesis.R`或`moat.threats` [§5][§6]。

**必答項**：三視角blind_spots各至少一條、不可調和矛盾的⚖裁決、`evidence_dismissed[]`(若有負向finding未落點)、`kill_metrics[]`、`rearm_trigger`。

---

## ⑤決策輸入與行動條件

**`decision_inputs`**（值可`null`，`dd_decision.py`機械路由裁決）七欄：`thesis_irreconcilable`(§4不可調和)｜`valuation_dependent`(re-rate貢獻≥Base IRR 40%；程式依你的情境算後覆寫，你填的僅供對照)｜`market_wrong_reason_given`(市場錯在哪的具體理由)｜`week26_return_pct`(26週漲幅)｜`momentum_overheated`(RSI 14d>70或4週漂移>+10%)｜`cycle_gates_pass`(反動能五閘全過，循環股)｜`consensus_rev_3m_pct`(FY1/FY2共識近3月上修%)，缺值`null`。覆寫層：`val_denominator_disputed`/`qc49_inherit_prior`+`prior_verdict`+`prior_role`/`held_now`(bool三態不可`"unknown"`代`null`)／`wait_for_price`+`wait_for_price_condition`(價格合理但要等：你的結論是「不追、等某價位或某事件」時填`true`並寫明等什麼，程式把進場改觀望，只往保守方向；沒有要等就填`null`)；`asym_ratio`/`irr_base_pct`/`ev5y_pct`一律`null` [§5]。

**問五｜估值**：判斷句＝現價要求未來發生什麼才划算，我信不信。`valuation.percentile_5y`(=(當前−5Y低)÷(5Y高−5Y低)×100%，必引`valuation_history`禁外推)｜`valuation.peg`(Non-GAAP 3年EPS CAGR，<1.0便宜/1~2合理/>2貴)｜`val_light`+`val_light_derivation`｜`upside_short_pct`/`upside_mid_pct`。分母含一次性效應→改前瞻錨定，若分母正是爭點→`val_denominator_disputed=true`且便宜論證無效並填`val_denominator_note`。條件式加尺：同業tier禁跨tier當anchor，依archetype定優先尺(商品循環P/B；複利Fwd P/E・PEG；未獲利EV/GP對照EV/S)。`appendix_a`四欄(`val`/`signal`/`ma`/`long_term_confidence`，全文見timing-appendix.md)：估值🔴+動能爆衝+品質A/B落B；`long_term_confidence`上限「中」：問三缺口無法歸因、或`capalloc_grade`=C [§2問五]。

**問四｜現金與資本配置**：判斷句＝`governance.capalloc_grade`；FCF/NI轉換率、SBC/營收、現金去向四分為最小交付。計分卡(唯一決定`capalloc_grade`)：M&A已實現ROIIC(≥WACC過)｜回購買入收益率(≥10Y殖利率+2%過)｜SBC淨稀釋率(≤1.5%/yr過)；≥2/3過=A、1項=B、0項=C。C級→信心上限「中」、天花板打8折。營運槓桿：Rev YoY−OI YoY，>3%壓縮列成長熄火。`governance.capital_returns`(成長靠併購撐時展開，未展開見共用約定) [§2問四]。

**必答項**：`decision_inputs`七欄、`governance.capalloc_grade`、`valuation.percentile_5y`、`valuation.peg`、`val_light`、`upside_short_pct`/`upside_mid_pct`、`appendix_a`四欄、`eps_meta`。`eps_meta.base_eps_path`＝共識三年錨，**物件不是陣列**：`{"FY2025A":基期實際,"FY2026E":x,"FY2027E":y,"FY2028E":z}`（基期鍵結尾必須是 A，程式靠它把基期排除在共識三年之外；不是情境樹終端年路徑）。

---

## 共用約定

- **未展開標記**：`industry.tam_table`/`growth.segments`/`governance.capital_returns`/`valuation.peers`為條件式；展開時該欄必須是陣列(`[{"item": "…", "value": "…"}]`，不得用物件裝散文)，不展開填`{"expanded": false, "reason": "…"}`缺一即無效；承重必須展開，理由不得只寫「營收占比低」[§0.5(二)]。
- **一次判斷、寫一遍**：同一結論只寫在權威欄一次；缺關鍵證據明說「證據包未涵蓋」並回報，不堆篇幅 [§0.5(三)]。
- **數字引用優先序（違反即無效輸出）**：承重數字一律引事實表`f_*` id(`fact_refs[]`)不重抄；沒有就是沒有，標「事實表未涵蓋」並回報點名，禁記憶或推估補、禁自行換算外推；RSI標不可用時`appendix_a`與`momentum_overheated`不得引用 [§6]。
- **推導可追溯**：承重結論數字須附「輸入數字→計算過程→implication」；你不自查，形狀由程式驗、判斷級🔴由跨模型閘擋 [§7]。

---

## 硬禁令

回覆全文即`judgment.json`內容(單輪、無工具、陣列外不得有文字)；不寫`scenario.json`(程式產生)；禁WebSearch/WebFetch(不足標「事實表未涵蓋」)；禁寫散文/HTML；禁Read `docs/dd/`既有報告、禁重讀自己寫出的檔；禁複製上一份報告結論文字；enum只准用本卡與bundle「②b enum表」列出的值(archetype.primary七類、confidence高/中/低、cycle_position五值、cycle_verdict四值皆在表內)，不譯成中文、不加註解；所有理由文字禁出現QC-數字/row 8a/8b/validator/機械閘等機制詞(機器語言外洩＝FAIL)；`kill_metrics[]`是陣列不是索引鍵物件 [§7][§5]。


---

## ⑤a 常載附卡：§5.R 報酬持續期檢核

<!-- source: .claude/skills/stock-analyst/references/roic-durability.md sha256:423416f648e1f2c6 git:8cfc0d5bd condensed:2026-09-16 model:sonnet -->
<!-- load-when: always（寫 §5 護城河前；與 archetype 無關，v19 ALWAYS_REFS） -->

# §5.R 報酬持續期檢核（ROIC durability）附卡

ROIC＝稅後營業利益率 × 投入資本周轉率（引 §7.E DuPont，不重算）。投入資本＝廠房設備＋存貨＋應收＋其他營運資產－應付等不計息營運負債。[§一]

## 一、當期 ROIC 四象限
| 象限 | 判讀要點 |
|---|---|
| 高利益率×高周轉 | 查持續期（下列四檢查點）[§一] |
| 高利益率×低周轉 | 查再投資負擔與資產更新週期[§一] |
| 低利益率×高周轉 | 易誤判為爛生意，先查 CCC 結構再下結論[§一] |
| 低利益率×低周轉 | ROIC 貼近資金成本，查成本曲線位置[§一] |

## 二、持續期四檢查點（每點輸出 🟢🟡🔴＋一個 sourced 證據＋代理變數讀數；不決定象限，決定當下利益率與周轉率能維持多久）[§二]
1. 需求基礎值：先分開使用者/決策者/付款者三角色，任一環節不成立再強的需求也轉不成收入；想要 vs 需要＝延後購買的代價；急迫性≠持久性；分開判斷「客戶要解決的問題」與「公司目前的解決方案」。[§二．1]
2. 決策層級：替代性要在決策的最小單位衡量，不是在商品層；供給者數量不足以衡量客戶眼中的替代性；可觀察代理變數＝漲價後流失率與使用量變化、分客群續約率、資料遷移所需時間、合約年限與違約條款、重新認證週期、換產品要重訓多少員工。[§二．2]
3. 價值鏈分配：先估整條價值鏈創造多少經濟利益，再判哪些環節最難取代（總量固定，某環節多拿即其他環節少拿）；觀察面＝各環節創造價值、採購金額占比、合約週期、產能狀況、買方集中度、客戶自建替代方案能力；重要互補品從多家供應收斂到單一供應會使公司失去定價空間；長期需求存在≠環節內公司能賺錢。[§二．3]
4. 社會容忍度：必需品價格彈性低但社會對大幅漲價的容忍度可能也低，兩者同時成立形成需求曲線上看不見的價格天花板；實際定價上限＝經濟上限與政治/社會上限中較小者；高必要×高敏感的公司刻意不把價格推到經濟上限＝保費；依賴監管授權的優勢＝政策風險，必查授權法源、修法程序、政策討論中是否已出現替代方案。[§二．4]

## 三、再投資空間（增量 ROIC）
內生成長率＝增量 ROIC × 再投資率，須用增量（過去資產拿高報酬不代表下一筆新增投資拿得到）。高 ROIC≠高成長，高 ROIC×低再投資空間仍可能是高價值公司；無法以良好報酬率再投資的現金留在公司不創造價值，應配回股東（→§9.D 檢核配發紀律）。刻意限制供給＝用短期成長換持續期，vs 用稀缺換成長（擴店/放寬授權/低價線）＝賭客群/產品/通路能否區隔，兩者都是管理層權衡，判讀時寫明公司選了哪邊、代價是什麼。結果寫入 dd-meta `endo_growth_ceiling`；本節是 ROIIC/再投資率/內生成長上界的唯一推導處，§6.D 與情境樹 sanity check 直接引用 `moat.roic_durability` 的數字，不重算、不另抄一組。[§三]

## 四、輸出紀律
分開判斷三件事並分別給結論：當期 ROIC（象限）、超額報酬持續時間（四檢查點）、新增資本報酬（增量 ROIC×再投資率）——才能看出漂亮損益表來自可延續的產業位置，還是一段剛好有利的時間。[§四]


---

## ⑤b 常載附卡：情境判斷問題字典

<!-- source: .claude/skills/stock-analyst/references/judgment-playbook.md sha256:19e76543dd53e334 git:8cfc0d5bd condensed:2026-09-16 model:sonnet -->
<!-- load-when: always（Part II 決策層動筆前；與 archetype 無關，v19 ALWAYS_REFS） -->

# 情境判斷問題字典附卡（QC-53）

命中條目核對判斷；核心研究已答的引用不重寫；未命中不答。

## 一、裁決與觸發器設計
1. 觀望/迴避錨型：估值貴→價格錨；thesis未決→事件錨(不設進場價)；趨勢未確認→技術錨；兩理由AND連接，錯配重寫。[§1]
2. if-then含「價格先走證據未到」分支：續漲未驗證→不追；跌但基本面無損→分批反買(非停損)。動作限{不追/停止加碼/分批反買/減碼/清倉}擇一。[§2]
3. 重啟：k-of-n(迴避3-of-3 AND，谷底2-of-3)；觸發後重跑DD非直接建倉；倉位角色降級(≤衛星starter)。[§3]
5. Override機械訊號：執行路徑須含「訊號證實為對」分支(數據點+期限+動作)。[§5]
6. 決勝數據不存在：settle數據今存在嗎/何時到/證據時間窗蓋風險窗嗎；不蓋→禁稱風險已解，可裁「不可裁決至{時點}」。[§6]
7. 分批/保留倉/trim標理由：動能過熱/估值/具名binary事件/波動(禁用)；保留tranche綁具名事件與解鎖條件；trim天花板須具體數字，自身倍數校準。[§7][§8]

## 二、證據品質
9. 品質指標歷史高檔(ROTCE/GM/NIM)：拆結構性/週期性/殘差，殘差定價進Bear機率與倉位。[§9]
10. 落後型風險指標(NPL/庫存/DSO)配導數級領先閘：兩量成長率差連2季超前＝觸發。[§10]
11. 管理層一次性歸因：不採信不否定，標「未證、監測」＋預登記「連N季X則歸因證偽」期限閘。[§11]
13. 內部人賣出：機制歸因(稅務vs主動)＋留存比例校準強度＋升級觸發＝不同角色更低價跟進。[§13]
16. §12a≥3不確定假設附「假設→Y5 EPS/目標價量化衝擊」表。[§16]
17. §2.F Single Thing須為數學上最大單一敏感度項，非最戲劇性。[§17]
19. FX/關稅/監管風險禁寫預測，指定公司損益層指標+門檻作「吸收失敗」判定閘。[§19]
20. 未決訴訟/監管：受影響營收數字+來源+settle日期；查程序性質(民事/刑事、個案/集體)；里程碑映動作(集體認證+不利和解→半倉；刑事介入→清倉)。[§20]

## 三、共識與市場結構
23. 賣方共識：目標價二次查核；現價vs均值方向幅度答支持/反對本裁決；全距max/min>2.5x→下調自身IRR/AR信心與倉位角色。[§23]
24. 賣方集體降評而進場：答分歧屬事實層或框架層，框架層→指明原多頭框架是否同本檔論點。[§24]
25. 裁決比共識悲觀：答市場錯誤假設(倍數regime/成長基準/模型依賴)；已跌X%不是安全邊際。[§25]
26. 利空sourced<1季：已進賣方模型嗎？未進→倉位下修一級＋凍結加碼至首個確認/否證數據點。[§26]

## 四、競爭、護城河與AI
27. 競爭證據挑戰moat_trend：分方向受損/速度放緩/客群範圍失守＋量化攻擊者資本量級；負面證據只記一次(level或trend擇一)。[§27]
28. 供給端替代性thesis按頭部與長尾分層檢驗。[§28]
29. thesis依賴產業順風：跨尺度規模對比戳破主題與吃到順風是否同命題；份額未證實時主題最多支撐觀望不支撐溢價。[§29]
30. AI曝險：淨增量式(新AI ARR>被蠶食收入才算加分，不看top-line)＋附著點(長在自有資產＝強化，繞過＝替代)，各給分界年。[§30]
31. moat_trend↓或共識連續下修：答Bear錨平穩嗎，每次下修下移地板→AR/正不對稱數字標失效禁作進場依據。[§31]
32. 頂部/波動處置：先答有無「核心可守」(thesis完整+through-cycle賺錢)，有→波動保護紀律；無→改循環交易紀律。[§32]


---

## ⑦ 前份判斷摘要（緊湊 JSON，≤ 5000 bytes）

```json
{"date":"20260518","verdict":"衛星候選 — turnaround thesis 已 5 季 confirmed (Aetna MBR 84.6% 改善 4.9pp + FY26 guidance raise) + 估值 🟢 便宜 (Fwd PE 11.5x 5Y 25% 分位 + PEG 0.94) + Pure MA ✅ 強勢；但 Oak Street $5.7B 減損結構失敗 + 高槓桿 D/E 1.06 / Net Debt/EBITDA 4.6x + dividend payout 192% 限制長期 compounder 潛力；trap 🟡 觀察期；建議等回測 $88-90 區分批入場","role":null,"H":{"status":"ok","format":"table","rows":[{"id":"H1","text":"Aetna MBR 收斂至 84-85% 穩態 + 維持規模","columns":{"2Y 驗證點":"FY2026 全年 MBR ≤ 86%","5Y 驗證點":"3Y 滾動均 MBR ≤ 85%","10Y 驗證點":"10Y MBR 穩定範圍","具體數字門檻":"FY26 MBR target 從管理層 reaffirm","信息來源":"公司季報 + Earnings Call","漂移觸發條件":"連 2 季 MBR > 86% → 削弱"}},{"id":"H2","text":"Oak Street loss 在 FY2027 前收窄至","columns":{"2Y 驗證點":"FY2026 EBIT loss 收窄至 $500M 內","5Y 驗證點":"FY2028 達 break-even 或微利","10Y 驗證點":"10Y 達成 segment level ~5% margin","具體數字門檻":"Q1 / Q4 segment 損益揭露","信息來源":"公司 segment reporting","漂移觸發條件":"FY2027 仍虧 > $500M → 反轉"}},{"id":"H3","text":"Caremark PBM + 整體 FCF ≥ $7.5B/年 維持 dividend 政策","columns":{"2Y 驗證點":"FY2026 FCF ≥ $7.5B","5Y 驗證點":"3Y 累積 FCF ≥ $24B","10Y 驗證點":"10Y Dividend 不被下修","具體數字門檻":"季報 FCF / dividend 公告","信息來源":"10-Q / 8-K","漂移觸發條件":"連 2 季 FCF"}}]},"R":{"status":"ok","format":"table","rows":[{"id":"R1","text":"Aetna H2 26 MBR 反彈","columns":{"對應假設":"H1","時間尺度":"🔥 中期","監測指標":"季度 MBR","警戒閾值":"連 2 季 > 86% 削弱、> 88% 反轉"}},{"id":"R2","text":"Oak Street 第二輪減損 / segment 出售","columns":{"對應假設":"H2","時間尺度":"🔥 中期","監測指標":"季度 Oak Street segment loss","警戒閾值":"FY27 仍虧 > $500M → 結構失敗"}},{"id":"R3","text":"PBM 監管立法（FTC rebate transparency）","columns":{"對應假設":"H3","時間尺度":"🐢 長期","監測指標":"FTC / Congress 立法進展","警戒閾值":"正式立法通過 → 削弱"}}]},"single_thing":null,"kill_metrics":null,"rearm_trigger":null,"irr_base_pct":null,"ev5y_pct":null,"drift_watch_prior":{"dca_verdict":null,"dca_role":null,"signal":"B","val":"🟢","ma":"✅","trap":"🟡","moat_trend":null,"runway_post_y5":null,"asym_ratio":null,"ev5y_pct":null,"irr_base_pct":null,"max_dd_pct":null,"bull_5y_price":null,"bear_5y_price":null,"p_bull_pct":null,"p_bear_pct":null,"rearm_trigger":null,"price_at_dd":95.82,"archetype":null,"cycle_position":null}}
```

---

## ⑦b 前份漂移歸因（機械閘逐欄對帳）

上面前份摘要的 `drift_watch_prior` 列了 20 欄前份值。`counter_evidence.contradictions[]` 內必須有條目的 `prior_field` 陣列**合起來涵蓋這 20 個欄名中除程式欄以外的每一個**（程式稍後才會算的 p_bull_pct／p_bear_pct／max_dd_pct，把它們歸進 `cause`=`價格變動` 或 `方法變動` 那條即可），每條 `cause` 三選一（`價格變動`／`新證據`／`方法變動`），漏一欄＝FAIL。`kill_metrics`／`rearm_trigger`／Single Thing 的門檻與前份不同時，另開一條 `cause`∈{`新證據`,`方法變動`}、`side_a`=舊門檻原文、`side_b`=新門檻原文，條目文字要含該動作名（如「清倉」「減碼」）；唯一致命點變動的那條文字要含「Single Thing」字樣，`side_a`=前份唯一致命點原文、`side_b`=本次原文。

`decision_inputs.ma`（週線均線六態）由程式從週線均線算出，值在事實表 `f_ma_state`：**照抄該值**，不得自判、不得填 ✅ 或「-」；程式落檔時會強制覆寫成事實表的值。**`ma`、`price_at_dd` 兩欄的漂移歸因由程式生成條目，你不要為它們開條目**；`asym_ratio`／`ev5y_pct`／`irr_base_pct`／`bull_5y_price`／`bear_5y_price` 的漂移歸因同樣由程式生成條目（程式用本次情境、依先換情境後換股價的順序拆量），你不要為它們開條目；裁決／角色若因 ma 變動而被矩陣改列，也由程式歸因。你只歸因基本面欄位（signal／val／trap／moat_trend／runway／archetype／情境輸入／門檻）。`oneliner` 不寫倉位角色字樣（核心／衛星／追蹤），角色由程式事後算。

**給讀者看的文字欄不准出現內部代號**：`thesis.H[]`／`thesis.R[]` 的各欄（信息來源／漂移觸發條件等）、`triggers[].text`、`counter_evidence.contradictions[]` 各欄、`answers.*.verdict`／`answers.*.reasoning` 這類文字，一律不得出現事實表 id（`f_` 開頭，如 `f_consensus_rev_3m_fy1_pct`）或軸／finding id（`軸名#n`，如 `competitive_share_entrants#0`）——這些是程式內部代號，不是給讀者的話。要引用哪個事實或哪個軸，寫進對應的 `fact_refs[]`／`evidence_refs[]` 陣列，文字欄本身只寫人話。

---

## 尾段：scenario_inputs 形狀與回覆格式

`scenario_inputs` 的鍵名與形狀必須完全照下面這份（不得增刪改名；程式據此產生 `dd_scenario.py` 的輸入檔，寫錯鍵名就是整段判斷失效）：

```json
{
  "terminal_label": "FY20XXE",
  "start": {"eps": <起點 EPS>, "pe": <起點 P/E＝price÷eps>, "basis": "<起點口徑一句話，TTM 或 FY1 須與終端倍數分母同口徑>"},
  "eps": {"bull": [<Y1>, <Y2>, <Y3>, <Y4>, <Y5>], "base": [五個數], "bear": [五個數]},
  "pe": {"bull": <終端倍數>, "base": <倍數>, "bear": <倍數>},
  "p": {"bull": <機率整數>, "base": <整數>, "bear": <整數>},
  "yield_pct": {"dividend": <股息殖利率 %>, "net_buyback": <淨回購殖利率 %>},
  "second_stage": {"bull_cagr_pct": <Y6–Y10 EPS CAGR %>, "base_cagr_pct": <%>},
  "max_dd": {"lo": <負數 %>, "hi": <負數 %>, "basis": "<範圍怎麼推出來的，見判斷卡③情境樹假設段>", "trigger_time": null},
  "basis": {"bull": "<這支路徑的假設一句>", "base": "…", "bear": "…"},
  "endo_ceiling_exceeded": <true|false，共識 CAGR 是否超過 §5.R 內生天花板>,
  "peer_max_fpe": <同業最高 Fwd P/E，可省略>
}
```

（共識三年 EPS 寫在 `eps_meta`，不要在這裡再寫一份；現價與共識由程式從事實表帶進 `scenario.json`。）

`dd_scenario.py` 會擋：`eps` 各路徑長度 ≠ 5、終端 EPS 非 Bear＜Base＜Bull、Bear 終端 EPS ＞ `consensus.fy2`、三機率加總 ≠ 100、`p.bear` ＜ 20、`endo_ceiling_exceeded=true` 且 `p.bear` ＜ 30、`p.base` ＞ 50。另有機械閘：Bull 前兩年 EPS 不得與 Base 相同（情境退化）、`|max_dd.lo|` 不得小於任一情境終點跌幅。機率與路徑是你的判斷，算術（IRR／三分量／AR／10Y）全由腳本算，不要自己填結果欄。

**回覆全文即 `judgment.json` 內容**：緊湊 JSON（`json.dumps(obj, separators=(",", ":"))` 等效格式），陣列外不得有任何文字（不加前言、不加 markdown 圍欄、不加附註）。不寫 `scenario.json`（程式從 `scenario_inputs` 產生）。不填不歸你的欄（`decision_inputs` 的機械欄、`reasoning`／`plain` 頂層、`moat.spread_table`／`competitors`、`contradictions`／`triggers` 等舊形狀頂層欄）——填了機械閘會擋。`decision_inputs.asym_ratio`／`irr_base_pct`／`ev5y_pct` 一律填 `null`，由腳本從 scenario 機械算回。

此回覆內容之後由程式存為 `/Users/ivanchang/financial-analysis-bot/.dd_build/runs/CVS_20261108/judgment.json`（你不用、也不能動筆存檔，只需回覆內容本身）。
